A Phase 2 interventional study of belimumab in Glomerulonephritis, Membranous, sponsored by GlaxoSmithKline. Completed at 8 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-10-13.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Glomerulonephritis, Membranous with a site in United Kingdom — 4 open to participants now, 5 under way, 2 of them phase 3. Glomerulonephritis, Membranous · United Kingdom.
Among the 12 studies in Glomerulonephritis, Membranous with a site in United Kingdom, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2012, is one of 7 in phase 2, and was the 2nd registered.
146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.
Browse Glomerulonephritis, Membranous studies →4 of the 12 studies in Glomerulonephritis, Membranous with a site in United Kingdom are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United Kingdom, United States, Belgium and 6 more countries
Ages 18–75
Vertex Pharmaceuticals Incorporated · Sites in United Kingdom, United States, Australia and 11 more countries
Ages 18–75
Alexion Pharmaceuticals, Inc. · Sites in United Kingdom, United States, Argentina and 7 more countries
Ages 18–75
UK Kidney Association · Sites in United Kingdom
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 2 · Phase 4 1
First in 2009; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 46 across 105 interventional studies indexed under Glomerulonephritis, Membranous.
Median enrollment 30 across the 11 interventional studies, 35,000 across the 1 observational. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 2 studies filed under Glomerulonephritis, Membranous — fewer than ten, so there is no comparison to draw.
2 of the studies in Glomerulonephritis, Membranous with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05707377Phase 3BeOne MedicinesA Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy | 2027-10 |
| NCT07157787Alexion Pharmaceuticals, Inc.Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | 2027-07-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Glomerulonephritis, Membranous with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase II, open label, experimental medicine study to evaluate the efficacy, safety and mechanism of action of belimumab in subjects with antiphospholipase A2 receptor (PLA2R) autoantibody positive idiopathic membranous glomerulonephropathy (IMGN), and to profile the relationship between biomarkers, autoantibody status and clinical response. 10 milligrams per kilogram (mg/kg) belimumab intravenous (IV) will be administered at weeks 0, 2, and then every 4 weeks, over a 24-week treatment period in subjects with anti-PLA2R antibody positive IMGN followed by a further long term treatment period until subjects reach remission of proteinuria, up to a maximum of 2 years total treatment. All subjects will receive background supportive therapy throughout the study. The dosing frequency will be adjusted to every 2 weeks if the subject's proteinuria as assessed by urinary protein creatinine ratio (PCR) is greater than 1000 milligrams per millimole (mg/mmol) [greater than 10 grams(g)/24 hours (h)], to compensate for loss of belimumab in the urine. Effects on mechanistic markers will be measured by the level of proteinuria, levels of anti-PLA2R antibodies, and various other measures of kidney function. These will be compared to historical data. The pharmacokinetics of belimumab will be measured to confirm dosing in heavily proteinuric subjects. Pharmacodynamic (PD) markers, biomarkers and Quality of Life(QoL) in IMGN subjects will also be investigated. Safety will be assessed by adverse events (AE), clinical laboratory evaluations, and vital signs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method. Child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until 16 weeks after the last dose
Exclusion Criteria:
or Have a planned surgical procedure or a history of any other medical disease (e.g. cardiopulmonary), laboratory abnormality, or condition (e.g. poor venous access) that, in the opinion of the investigator, makes the subject unsuitable for the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10mg/kg belimumab intravenous (IV) administered at weeks 0 and 2, and then every 4 weeks, over a 24-week treatment period, resulting in a total of 8 doses, and will be assessed for the primary endpoint at week 28. Subjects will then enter the long term phase of the study and receive 10mg/kg belimumab every 4 weeks until week 100,or until they have been in complete remission for at least 3 months, resulting in up to 27 doses.
Drug: belimumab
10mg/kg administered intravenously
Change From Baseline in Proteinuria Levels at Week 28
Proteinuria based on urinary protein creatinine ratio (PCR) was measured from 2 consecutive 24 hour (h) urine collection pre and post dosing at Baseline and Week 28 and the mean PCR was determined at each time point. Baseline is defined as the mean of the pre and post dosing Day 0 values. The ratio is defined as the Week 28 value divided by the Baseline value. Ratio to Baseline: Estimated value = 0.76, 2-sided 95% confidence interval (CI)=0.57 to 1.01. The geometric mean method was used to calculate the CI. The analysis was performed on Intent-to-treat (ITT) Population which comprised of all eligible participants who received at least one dose of investigational drug. Only those participants available at the indicated time point (Week 28) were analyzed.
Time frame: Baseline and Week 28
Change From Baseline in Anti-phospholipase A2 Receptor (PLA2R) Autoantibody Titers at Week 28
PLA2R autoantibody titers in serum were analyzed at Baseline and Week 28 by means of a validated anti- PLA2R enzyme linked immunosorbent assay (ELISA) from EuroImmun. Baseline is defined as the Day 0 value and change from Baseline was calculated as ratio to Baseline by dividing the Week 28 values with the Baseline values. Ratio to Baseline: Estimated value = 0.27, 2-sided 95% CI=0.12 to 0.58. The geometric mean method was used to calculate the CI.
Time frame: Baseline and Week 28
Proteinuria Levels at the Indicated Time Points
Proteinuria based on urinary protein creatinine ratio (PCR) measured from 2 consecutive 24h urine collections at Baseline and Week 28, from a pre-intervention spot urine sample and 24 hour urine collection after visit at Weeks 12, 52, 76 and 104, and from a spot urine sample at week 128. Mean PCR was calculated at each time point where there were 2 samples. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Week 12, 28, 52, 76, 104 and 128/6 month follow-up
Change From Baseline in Proteinuria Levels at the Indicated Time Points
Proteinuria based on urinary protein creatinine ratio (PCR) measured from 2 consecutive 24h urine collections at Baseline and Week 28, from a pre-intervention spot urine sample and 24 hour urine collection after visit at Weeks 12, 52, 76 and 104, and from a spot urine sample at week 128. Mean PCR was calculated at each time point where there were 2 samples. Baseline is defined as Day 0 value and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Week 12, 28, 52, 76, 104 and Week 128/6 month follow up
Anti-phospholipase A2 Receptor (PLA2R) Autoantibody Levels at Indicated Time Points
Anti-PLA2R autoantibody titers in serum were analyzed by means of a validated anti-PLA2R enzyme linked immunosorbent assay (ELISA) assay from Euroimmun. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Week 12, 28, 52, 76, 104 and 128/6 month follow-up
Change From Baseline in Anti-PLA2R Autoantibody Titers at the Indicated Time Points
Anti-PLA2R autoantibody titers in serum were analyzed by means of a validated anti- PLA2R enzyme linked immunosorbent assay (ELISA) from Euroimmun. Baseline is defined as the Day 0 value and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128.
Number of Participants With Complete or Partial Remission
Complete remission is defined as PCR \<30 mg/mmol (proteinuria \<0.3grams \[g\]/24 h) with no worsening in renal function (estimated glomerular filtration rate \[eGFR\] reduction from Baseline \<15 percent). Partial remission is defined as PCR \<350 mg/mmol (proteinuria \<3.5 g/24 h) but \>= 30 mg/mmol (proteinuria \>= 0.3g/24h) and decrease of \>50 percent from Day 0 Baseline, together with no consistent worsening in renal function (eGFR reduction from Baseline \<15percent). Only those participants available at the specified time points were analyzed (represented by n=X in category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128
Time to Complete or Partial Remission
Time to complete or partial remission was estimated using the Kaplan-Meier method. Complete remission is defined as PCR \<30 mg/mmol (proteinuria \<0.3g/24 h) with no worsening in renal function (eGFR reduction from Baseline \<15 percent ). Partial remission is defined as PCR \<350 mg/mmol (proteinuria \<3.5 g/24 h) but \>= 30 mg/mmol (proteinuria \>= 0.3g/24h) and decrease of \>50 percent from Day 0 Baseline, together with no consistent worsening in renal function (eGFR reduction from Baseline \<15 percent). Only 1 participant reached complete remission. Hence, statistical analysis for complete remission was not performed.
Time frame: Baseline and up to Week 128/6 month follow up
Duration of Complete or Partial Remission
Complete remission is defined as PCR \<30 mg/mmol (proteinuria \<0.3g/24 h) with no worsening in renal function (eGFR reduction from Baseline \<15percent). Partial remission is defined as PCR \<350 mg/mmol (proteinuria \<3.5 g/24 h) but \>= 30 mg/mmol (proteinuria \>= 0.3g/24h) and decrease of \>50% from Day 0 Baseline, together with no consistent worsening in renal function (eGFR reduction from Baseline \<15percent). Only those participants available at the specified time points were analyzed (represented by n=X in category titles). NA indicates that data was not available as only 1 participant reached complete remission. Hence, standard deviation for complete remission was not calculated.
Time frame: Baseline and up to Week 128/6 month follow up
Number of Participants With PLA2R Autoantibody Remission
Incidence of anti-PLA2R autoantibody remission were evaluated by full response and partial response. Full response is defined as antibody undetectable, partial response is defined as reduction in titers by 50 percent. For anti PLA2R autoantibody data, log transformation was applied before the formal analyses. Anti-PLA2R autoantibody blood samples were evaluated at Week 12, 28, 52, 76, 104 and 128/6 week post last-dose. Only those participants available at the specified time points were analyzed (represented by n=X in category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128
Time to Anti-PLA2R Autoantibody Remission
Time to anti-PLA2R autoantibody remission was estimated using Kaplan-Meier method for full response and partial response full response with antibody undetectable and partial response with reduction in titers by 50 percent.
Time frame: Baseline and up to Week 128/6 month follow up
Number of Participants With Anti-PLA2R Autoantibody Relapse
Incidence of anti-PLA2R autoantibody relapse defined as antibody detectable after previously undetectable. Anti-PLA2R autoantibody blood samples were evaluated at Week 12, 28, 52, 76, 104/4 week post last dose, Only those participants available at the specified time points were analyzed (represented by n=X in category titles).
Time frame: Baseline and up to Week 128/6 month follow up
eGFR Levels at the Indicated Time Points
eGFR was assessed from levels of creatinine using the 4 variable version of the modification of diet in renal disease (MDRD) equation as recommended by National Kidney Foundation-Chronic Kidney Disease (NKF-CKD) guidelines. Baseline for eGFR is defined as the mean of the screening and Day 0 values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128/6 month follow-up.
Change From Baseline in eGFR Levels at the Indicated Time Points
eGFR was assessed from levels of creatinine using the 4 variable version of the modification of diet in renal disease (MDRD) equation as recommended by national kidney foundation-chronic kidney disease (NKF-CKD) guidelines. Baseline for eGFR is defined as the mean of the Screening and Day 0 values and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and up to Week 128/6 month follow up
Serum Creatinine Levels at the Indicated Time Points
Serum creatinine was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum creatinine is defined as the mean of the Screening and Day 0 values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128/6 month follow-up
Change From Baseline in Serum Creatinine Levels at the Indicated Time Points
Serum creatinine was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum creatinine is defined as the mean of the Screening and Day 0 values and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128/6 month follow-up
Serum Albumin Levels at Indicated Time Points
Serum albumin was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum albumin is defined as the mean of the Screening and Day 0 values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128/6 month follow-up.
Change From Baseline in Levels of Serum Albumin at the Indicated Time Points
Serum albumin was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum albumin is defined as the mean of the Screening and Day 0 values and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128/6 month follow-up
Serum Cholesterol Levels at Indicated Time Points
Serum cholesterol was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum cholesterol is defined as the mean of the Screening and Day 0 values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128/6 month follow-up
Change From Baseline in Serum Cholesterol at the Indicated Time Points
Serum cholesterol was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum cholesterol is defined as the mean of the Screening and Day 0 values and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128/6 month follow-up
Serum Immunoglobulin G (IgG) Levels at Indicated Time Points
Serum IgG was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum IgG is defined as the pre-dose Day 0 value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128/6 month follow-up
Change From Baseline in Serum IgG at the Indicated Time Points
Serum IgG was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum IgG is defined as the pre-dose Day 0 value and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, 104 and 128/6 month follow up
Number of Participants With Edema and Edema Extending Beyond Calf
Reduction of proteinuria lessens the risk of thromboembolic and cardiovascular effects and reduces the edema in participants. Investigators physically reviewed participants for clinical manifestations of idiopathic membranous glomerulonephropathy (IMGN) (e.g. edema extending beyond calf) during study and analysis was performed at Week 12, 28, 52, 76 Week 104. Only those participants available at the specified time points were analyzed (represented by n=X in category titles).
Time frame: Baseline and Weeks 12, 28, 52, 76, and 104
Summary of Maximum Observed Serum Concentration (Cmax) of Belimumab at the Indicated Time Points
The first occurrence of Cmax was determined directly from the serum concentration-time data. The pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis and all calculations of non-compartmental parameters are being based on actual sampling times.
Time frame: Baseline and up to 4 week post last dose
Summary of Minimum Observed Concentration (Cmin) of Belimumab at the Indicated Time Points
Trough concentration (Cmin) samples collected on the specified days are being used to assess attainment whether there was sufficient belimumab despite it being lost in the urine from the proteinuria and to check if it improved as proteinuria resolved. Analysis was performed on pre-infusion samples at weeks 2,4,8,12,28,40,52,76 and the 4 week post last-dose.
Time frame: Baseline and up to 4 week post last dose
Summary of Area Under the Serum Concentration-time Curve to the Last Quantifiable Concentration (AUC[0-2])
The AUC(0-2) was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Blood samples for PK analysis were collected at the following time points: pre-dose (on dosing days): Days 0, 1, 4, 7, 14 and Week 4, 8, 12, 28, 40, 52, 76 and 4 week post last dose. Post-dose (5 minutes after dosing complete): Days 0 and 28. The results will be posted at later date following post hoc analysis.
Time frame: Baseline and up to 4 week post last dose
Summary of Total Amount of Urine Excreted Ae(0-24)
PK parameters from the urine concentration data: urine Ae(0-24) were assessed. 24 h urine collections for PK analysis were collected after the Day 0 and Weeks 12, 28, 52, 76 doses and at the 4 week post last dose visit. A population approach was undertaken to characterize the population PK parameters and associated variability of belimumab in nephrotic participants. The population approach could have provided derived clearance of belimumab for each participant after the first dose. The population PK analysis was conducted using nonlinear mixed-effect modeling (NONMEM) or appropriate nonlinear mixed-effect analysis software. Several samples were taken pre-dose at Day 0 and some at week 12 incorrectly which affects interpretation.
Time frame: Baseline and Up to 4 week post last dose
Change From Baseline in Short Form (SF)-36 v2 Quality of Life (QoL) Questionnaire Score
Health-related quality of life was assessed through participant self-completion of the short form health survey (SF-36 version \[v2\]), a general health related quality of life metrics. Norm-based Scores (NBS) for physical functioning, role emotional, role physical were assessed. The remaining SF-36 component scores require re-scaling and therefore will be added at a later date. SF-36 was administered prior to any procedures at Weeks 12, 28, 52, 76 and 104/4 week post last dose. Item score were recorded and higher score represented better health status. Baseline is defined as Day 0 pre dose value and change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. Only those participants available at the specified time points were analyzed (represented by n=X in category titles).
Time frame: Baseline and up to Week 104/4 week post last dose
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The analysis was performed on Safety Population which comprised of all participants who were randomized into the study. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, Requires hospitalization or prolongation of existing hospitalization, Results in disability/incapacity, is a congenital anomaly/birth defect, may require medical or surgical intervention, is associated with liver injury and impaired liver function.
Time frame: Baseline and up to Week 128/6 month follow up
Number of Participants With Abnormal Clinical Chemistry and Hematology Values
Blood samples were collected from participants for evaluation of clinical chemistry and hematology parameters. The clinical chemistry parameters included albumin, alkaline phosphatase (alk.phosph.), alanine amino transferase (ALT), aspartate amino transferase (AST), total and direct bilirubin, calcium, cholesterol, chloride, carbon dioxide, creatinine, gamma glutamyl transferase (GGT), glucose, potassium, lactate dehydrogenase (LD), magnesium, sodium, phosphorus, total protein, blood urea nitrogen (BUN) and uric acid. The hematology parameters included basophils, eosinophil, hemoglobin, hematocrit, lymphocytes, monocytes, total neutrophils, platelets, red blood cells (RBC) count and white blood cells (WBC) count. Participants were counted in the category that their value changes to (low or high) for the specific time points. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and up to Week 116/16 week follow-up visit
Number of Participants With Urinalysis Dipstick Findings
Urine samples were collected for urinalysis by dipstick method from Baseline up to Week 116/16 months follow up and number of participants with findings were presented for Baseline, Week 12, 28, 52, 76, 104/4 weeks post last-dose and Week 116/16 week follow up (WF). The urinalysis parameters included occult blood, glucose, ketones, protein. The findings were presented as trace or 1/10 g/100 milliliter (dL), trace, negative, 4+, 3+, 3+ or 1 g/dL, 2+ or 1/2 g/dL, 2+, 1+ or 1/4 g/dL and 1+. Only participants present at the specific time points were presented (represented by n=X in the category titles).
Time frame: Baseline and up to Week 116/16 Week follow up
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP were measured from Baseline throughout the treatment period up to Week 116/ 16 week follow-up visit. The Baseline value was taken at Day 0 pre dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean and standard deviation (SD) were measured and presented for Week 12, 28, 52, 76, 104 withdrawn visit, 4 Week post last dose and 16 Week follow-up visit. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to week 116/16 week follow-up visit
Change From Baseline in Pulse Rate
Pulse rate was measured from Baseline throughout the treatment period up to Week 116/ 16 week follow-up visit. The Baseline value was taken at Day 0 pre dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean and standard deviation (SD) were measured and presented for Week 12, 28, 52, 76, 104 withdrawn visit, 4 Week post last dose and 16 Week post last dose visits. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Week 116/16 week follow-up visit
Change From Baseline in Temperature
Temperature was measured from Baseline throughout the treatment period up to Week 116/ 16 week follow-up visit. The Baseline value was taken at Day 0 pre dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean and standard deviation (SD) were measured and presented for Week 12, 28, 52, 76, 104 withdrawn visit, 4 Week post last dose and 16 week post last dose visits. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline and up to Week 116/16 week follow-up visit
Number of Participants With Positive Immunogenicity Findings
Blood samples of participants were collected pre-dose on Weeks 0, 12, 28, 40, 52, 76, 4 week post last dose and 16 week post last dose visit for belimumab immunogenicity assay. No participants showed positive immunogenicity findings.
Time frame: Baseline and up to Week 116/16 week follow-up visit
Urine Membrane Attack Complex (MAC) Levels
Urine membrane attack complex was assayed quantitatively by ELISA method. Urine MAC samples were collected at Day 0 and Weeks 8, 28, 52, 76 and 4 week post last dose. Results were normalized using urine creatinine concentration to adjust for urine dilution. Endpoint was moved to 'Exploratory' in Protocol amendment 5 as risk of availability of functioning assay for urine membrane attack complex was noted. No assay was subsequently found and samples were not analyzed
Time frame: Baseline and up to 4 week post last dose
Change From Baseline in Urine Membrane Attack Complex (MAC)
Urine membrane attack complex will be assayed quantitatively by ELISA method. Urine MAC samples are being collected at Day 0 and Weeks 8, 28, 52, 76 and 4 week post last dose. Results will be normalized using urine creatinine concentration to adjust for urine dilution, before calculation of the ratio as value at time point divided by value at Baseline (Day 0). Endpoint was changed to 'exploratory' as risk of availability of functioning assay for urine membrane attack complex was noted. No assay was subsequently found and samples were not analyzed.
Time frame: Baseline and up to 4 week post last dose
Change From Baseline in B Cell and T Cell Markers Concentration
B cell Facs panels were used to measure changes over the course of therapy in B cell subsets such as transitional, naïve, memory and plasma B cell compartments by percent of the B cell compartments and absolute numbers. T cell Facs panel were used to measure changes in T cell subsets, such as T regs and CD4+ and CD8+ T cells, in terms of numbers and expression of activation markers to establish if B cell targeting with belimumab affects the T cell compartment perhaps through limiting B cell antigen presentation or cytokine release. Baseline is defined as Day 0 value and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
Time frame: Baseline and up to Week 128/6 month post last dose
Change From Baseline in Cytokines/Chemokine
Cytokine/chemokine associated with T helper skewing or autoimmune pathology will be analyzed using Luminex, ELISA. Serum analyte quantification were used to confirm altered protein levels of any gene expression increases or decreases identified by transcriptomic analysis. Endpoint was moved to 'Exploratory' in Protocol amendment 5 as benefits of assessing cytokines was deemed low. Samples were not analyzed.
Time frame: Baseline and up to Week 104/4 week post last dose
Serum BLys Levels
Free BLyS protein were analyzed using an ELISA. Serum samples were collected before treatment and after belimumab washout at Week 0 and Week 116/16 week follow-up visit.
Time frame: Baseline and Week 116/16 week follow-up visit
Urine BLys Levels as a Ratio to Creatinine
B lymphocyte stimulator (BLyS) normalized by creatinine as a ratio of BLyS: creatinine. Free BLyS protein is being analyzed using an ELISA. Urine samples are being collected before treatment and after belimumab washout at Week 0 and Week 116/16 week follow-up visit. Only raw BLyS values available and unable to be assessed due to lack of comparison to a creatinine as a urine concentration marker.
Time frame: Baseline and Week 116/16 week follow-up visit
Eligible participants were recruited from July 2012 until March 2014, into this 2 part study of a initial treatment phase, a long term treatment phase, and then followed up for a further 6 months. Results have previously been presented for the initial treatment phase, up to the Week 28 and are now presented for the completed study.
| Milestone | Belimumab 10 mg/kg IV |
|---|---|
| Started | 14 |
| Completed | 8 |
| Not completed | 6 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Other: reached stopping criteria | 1 |
| Withdrew: Other:treatment stopped due to remission | 1 |
Proteinuria based on urinary protein creatinine ratio (PCR) was measured from 2 consecutive 24 hour (h) urine collection pre and post dosing at Baseline and Week 28 and the mean PCR was determined at each time point. Baseline is defined as the mean of the pre and post dosing Day 0 values. The ratio is defined as the Week 28 value divided by the Baseline value. Ratio to Baseline: Estimated value = 0.76, 2-sided 95% confidence interval (CI)=0.57 to 1.01. The geometric mean method was used to calculate the CI. The analysis was performed on Intent-to-treat (ITT) Population which comprised of all eligible participants who received at least one dose of investigational drug. Only those participants available at the indicated time point (Week 28) were analyzed.
| Ratio | Belimumab 10 mg/kg IV |
|---|---|
| Change From Baseline in Proteinuria Levels at Week 28 | 0.7552 ± 45.0 |
PLA2R autoantibody titers in serum were analyzed at Baseline and Week 28 by means of a validated anti- PLA2R enzyme linked immunosorbent assay (ELISA) from EuroImmun. Baseline is defined as the Day 0 value and change from Baseline was calculated as ratio to Baseline by dividing the Week 28 values with the Baseline values. Ratio to Baseline: Estimated value = 0.27, 2-sided 95% CI=0.12 to 0.58. The geometric mean method was used to calculate the CI.
| Ratio | Belimumab 10 mg/kg IV |
|---|---|
| Change From Baseline in Anti-phospholipase A2 Receptor (PLA2R) Autoantibody Titers at Week 28 | 0.2666 ± 171.0 |
Proteinuria based on urinary protein creatinine ratio (PCR) measured from 2 consecutive 24h urine collections at Baseline and Week 28, from a pre-intervention spot urine sample and 24 hour urine collection after visit at Weeks 12, 52, 76 and 104, and from a spot urine sample at week 128. Mean PCR was calculated at each time point where there were 2 samples. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| milligrams per millimole (mg/mmol) | Belimumab 10 mg/kg IV |
|---|---|
| Baseline, n=14 | 724.3157 ± 40.2 |
| Week 12, n=13 | 670.8655 ± 46.9 |
| Week 28, n=11 | 498.1255 ± 40.9 |
| Week 52, n=9 | 356.4209 ± 174.8 |
| Week 76, n=8 | 274.9714 ± 70.4 |
| Week 104, n=10 | 129.9761 ± 186.0 |
| Week 128, n=9 | 75.2359 ± 136.4 |
Proteinuria based on urinary protein creatinine ratio (PCR) measured from 2 consecutive 24h urine collections at Baseline and Week 28, from a pre-intervention spot urine sample and 24 hour urine collection after visit at Weeks 12, 52, 76 and 104, and from a spot urine sample at week 128. Mean PCR was calculated at each time point where there were 2 samples. Baseline is defined as Day 0 value and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Ratio | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; n= 13 | 0.9437 ± 39.3 |
| Week 28; n= 11 | 0.7552 ± 45.0 |
| Week 52; n= 9 | 0.5297 ± 206.7 |
| Week 76; n= 8 | 0.4177 ± 54.3 |
| Week 104; n= 10 | 0.1874 ± 189.3 |
| Week 128; n= 9 | 0.1118 ± 139.1 |
Anti-PLA2R autoantibody titers in serum were analyzed by means of a validated anti-PLA2R enzyme linked immunosorbent assay (ELISA) assay from Euroimmun. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| relative units per milliliter (RU/mL) | Belimumab 10 mg/kg IV |
|---|---|
| Baseline, n=14 | 168.3 ± 138.9 |
| Week 12, n=13 | 91.0 ± 200.4 |
| Week 28, n=11 | 46.4 ± 319.6 |
| Week 52, n=9 | 12.9 ± 358.4 |
| Week 76, n=8 | 7.5 ± 140.4 |
| Week 104, n=10 | 3.7 ± 72.7 |
| Week 128, n=8 | 4.4 ± 112.0 |
Anti-PLA2R autoantibody titers in serum were analyzed by means of a validated anti- PLA2R enzyme linked immunosorbent assay (ELISA) from Euroimmun. Baseline is defined as the Day 0 value and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Ratio | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; n= 13 | 0.5362 ± 58.1 |
| Week 28; n= 11 | 0.2666 ± 171.0 |
| Week 52; n= 9 | 0.0737 ± 130.3 |
| Week 76; n= 8 | 0.0436 ± 102.8 |
| Week 104; n= 10 | 0.0212 ± 169.1 |
| Week 128; n= 8 | 0.0284 ± 243.7 |
Complete remission is defined as PCR \<30 mg/mmol (proteinuria \<0.3grams \[g\]/24 h) with no worsening in renal function (estimated glomerular filtration rate \[eGFR\] reduction from Baseline \<15 percent). Partial remission is defined as PCR \<350 mg/mmol (proteinuria \<3.5 g/24 h) but \>= 30 mg/mmol (proteinuria \>= 0.3g/24h) and decrease of \>50 percent from Day 0 Baseline, together with no consistent worsening in renal function (eGFR reduction from Baseline \<15percent). Only those participants available at the specified time points were analyzed (represented by n=X in category titles).
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; Partial remission; n= 13 | 0 |
| Week 12; Complete remission; n= 13 | 0 |
| Week 28; Partial remission; n= 11 | 1 |
| Week 28; Complete remission; n= 11 | 0 |
| Week 52; Partial remission; n= 9 | 2 |
| Week 52; Complete remission; n= 9 | 1 |
| Week 76; Partial remission; n= 8 | 3 |
| Week 76; Complete remission; n= 8 | 0 |
| Week 104; Partial remission; n= 10 | 6 |
| Week 104; Complete remission; n= 10 | 1 |
| Week 128; Partial remission; n= 9 | 6 |
| Week 128; Complete remission; n= 9 | 1 |
Time to complete or partial remission was estimated using the Kaplan-Meier method. Complete remission is defined as PCR \<30 mg/mmol (proteinuria \<0.3g/24 h) with no worsening in renal function (eGFR reduction from Baseline \<15 percent ). Partial remission is defined as PCR \<350 mg/mmol (proteinuria \<3.5 g/24 h) but \>= 30 mg/mmol (proteinuria \>= 0.3g/24h) and decrease of \>50 percent from Day 0 Baseline, together with no consistent worsening in renal function (eGFR reduction from Baseline \<15 percent). Only 1 participant reached complete remission. Hence, statistical analysis for complete remission was not performed.
| Weeks | Belimumab 10 mg/kg IV |
|---|---|
| Time to Complete or Partial Remission | 68.20 (28.00 to 93.60) |
Complete remission is defined as PCR \<30 mg/mmol (proteinuria \<0.3g/24 h) with no worsening in renal function (eGFR reduction from Baseline \<15percent). Partial remission is defined as PCR \<350 mg/mmol (proteinuria \<3.5 g/24 h) but \>= 30 mg/mmol (proteinuria \>= 0.3g/24h) and decrease of \>50% from Day 0 Baseline, together with no consistent worsening in renal function (eGFR reduction from Baseline \<15percent). Only those participants available at the specified time points were analyzed (represented by n=X in category titles). NA indicates that data was not available as only 1 participant reached complete remission. Hence, standard deviation for complete remission was not calculated.
| Days | Belimumab 10 mg/kg IV |
|---|---|
| Complete remission; n= 1 | 365.0 ± NA |
| Partial remission; n= 9 | 378.6 ± 186.15 |
Incidence of anti-PLA2R autoantibody remission were evaluated by full response and partial response. Full response is defined as antibody undetectable, partial response is defined as reduction in titers by 50 percent. For anti PLA2R autoantibody data, log transformation was applied before the formal analyses. Anti-PLA2R autoantibody blood samples were evaluated at Week 12, 28, 52, 76, 104 and 128/6 week post last-dose. Only those participants available at the specified time points were analyzed (represented by n=X in category titles).
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; full response; n= 13 | 1 |
| Week 12; partial response; n= 13 | 3 |
| Week 28; full response; n= 11 | 3 |
| Week 28; partial response; n= 11 | 6 |
| Week 52; full response; n= 9 | 4 |
| Week 52; partial response; n= 9 | 5 |
| Week 76; full response; n= 8 | 4 |
| Week 76; partial response; n= 8 | 4 |
| Week 104; full response; n= 10 | 10 |
| Week 104; partial response; n= 10 | 0 |
| Week 128; Full response; n= 8 | 8 |
| Week 128; partial response; n= 8 | 0 |
Time to anti-PLA2R autoantibody remission was estimated using Kaplan-Meier method for full response and partial response full response with antibody undetectable and partial response with reduction in titers by 50 percent.
| Weeks | Belimumab 10 mg/kg IV |
|---|---|
| Partial response | 16.20 (8.00 to 24.00) |
| Complete response | 82.00 (16.00 to 92.00) |
Incidence of anti-PLA2R autoantibody relapse defined as antibody detectable after previously undetectable. Anti-PLA2R autoantibody blood samples were evaluated at Week 12, 28, 52, 76, 104/4 week post last dose, Only those participants available at the specified time points were analyzed (represented by n=X in category titles).
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; n= 13 | 0 |
| Week 28; n= 11 | 0 |
| Week 52; n= 9 | 0 |
| Week 76; n= 8 | 0 |
| Week 104; n= 10 | 0 |
| Week 128; n= 8 | 0 |
eGFR was assessed from levels of creatinine using the 4 variable version of the modification of diet in renal disease (MDRD) equation as recommended by National Kidney Foundation-Chronic Kidney Disease (NKF-CKD) guidelines. Baseline for eGFR is defined as the mean of the screening and Day 0 values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| milliliter/minute (mL/min/1.73meter^2) | Belimumab 10 mg/kg IV |
|---|---|
| Baseline; n= 14 | 69.8170 ± 32.9 |
| Week 12; n= 13 | 66.2639 ± 35.4 |
| Week 28; n= 11 | 65.0866 ± 36.1 |
| Week 52; n= 7 | 65.1308 ± 45.0 |
| Week 76; n= 8 | 61.6732 ± 47.1 |
| Week 104; n= 10 | 69.7692 ± 39.1 |
| Week 128; n= 9 | 64.7984 ± 39.2 |
eGFR was assessed from levels of creatinine using the 4 variable version of the modification of diet in renal disease (MDRD) equation as recommended by national kidney foundation-chronic kidney disease (NKF-CKD) guidelines. Baseline for eGFR is defined as the mean of the Screening and Day 0 values and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Ratio | Belimumab 10 mg/kg IV |
|---|---|
| Week 2, n=14 | 0.9954 ± 10.8 |
| Week 4, n= 13 | 0.9190 ± 16.4 |
| Week 8, n= 13 | 0.9035 ± 16.2 |
| Week 12, n= 13 | 0.9339 ± 17.1 |
| Week 16, n= 12 | 0.9521 ± 12.5 |
| Week 20, n= 8 | 0.9819 ± 11.8 |
| Week 24, n= 11 | 0.9274 ± 17.1 |
| Week 28, n= 11 | 0.9694 ± 21.1 |
| Week 32, n= 9 | 1.0099 ± 19.5 |
| Week 36, n= 11 | 0.9692 ± 17.4 |
| Week 40, n= 11 | 0.9425 ± 20.8 |
| Week 44, n= 10 | 0.9531 ± 22.6 |
| Week 48, n= 8 | 0.9929 ± 23.8 |
| Week 52, n= 7 | 0.9290 ± 27.7 |
| Week 56, n= 9 | 1.0181 ± 21.9 |
| Week 60, n= 9 | 0.9805 ± 26.8 |
| Week 64, n=9 | 1.0217 ± 23.5 |
| Week 68, n=8 | 1.0233 ± 24.6 |
| Week 72, n=8 | 1.0168 ± 28.3 |
| Week 76, n=8 | 1.0055 ± 33.3 |
| Week 80, n=8 | 1.0431 ± 21.6 |
| Week 84, n=8 | 0.9959 ± 25.3 |
| Week 88, n=8 | 1.0529 ± 16.3 |
| Week 92, n=8 | 1.0052 ± 26.3 |
| Week 96, n=8 | 1.1204 ± 22.1 |
| Week 100, n=8 | 1.1122 ± 24.7 |
| Week 104, n=10 | 1.0480 ± 23.3 |
| Week 116; n= 8 | 1.0373 ± 19.8 |
| Week 128, n=9 | 0.9971 ± 35.2 |
Serum creatinine was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum creatinine is defined as the mean of the Screening and Day 0 values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| micromoles/liter (µmol/L) | Belimumab 10 mg/kg IV |
|---|---|
| Baseline; n= 14 | 97.1658 ± 22.8 |
| Week 12; n= 13 | 100.6421 ± 26.8 |
| Week 28; n= 11 | 99.9535 ± 24.8 |
| Week 52; n= 7 | 96.6583 ± 30.2 |
| Week 76; n= 8 | 103.0265 ± 32.8 |
| Week 104; n= 10 | 92.4547 ± 29.6 |
| Week 128; n= 9 | 97.7260 ± 29.7 |
Serum creatinine was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum creatinine is defined as the mean of the Screening and Day 0 values and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Ratio | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; n= 13 | 1.0530 ± 14.8 |
| Week 28; n= 11 | 1.0202 ± 18.6 |
| Week 52; n= 7 | 1.0581 ± 23.7 |
| Week 76; n= 8 | 0.9818 ± 28.7 |
| Week 104; n= 10 | 0.9467 ± 20.1 |
| Week 128; n= 9 | 0.9874 ± 30.4 |
Serum albumin was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum albumin is defined as the mean of the Screening and Day 0 values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| grams per liter (g/L) | Belimumab 10 mg/kg IV |
|---|---|
| Baseline; n= 14 | 23.3306 ± 22.7 |
| Week 12; n= 13 | 24.4204 ± 27.5 |
| Week 28; n= 11 | 27.8397 ± 23.4 |
| Week 52; n= 7 | 31.9927 ± 18.3 |
| Week 76; n= 8 | 33.9484 ± 10.9 |
| Week 104; n= 10 | 39.1015 ± 7.5 |
| Week 128; n= 9 | 39.2009 ± 8.8 |
Serum albumin was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum albumin is defined as the mean of the Screening and Day 0 values and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| ratio | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; n= 13 | 1.0324 ± 15.0 |
| Week 28; n= 11 | 1.1211 ± 16.9 |
| Week 52; n= 7 | 1.2828 ± 28.1 |
| Week 76; n= 8 | 1.3695 ± 23.8 |
| Week 104; n= 10 | 1.5879 ± 19.6 |
| Week 128; n= 9 | 1.5799 ± 24.7 |
Serum cholesterol was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum cholesterol is defined as the mean of the Screening and Day 0 values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| millimoles per liter (mmol/L) | Belimumab 10 mg/kg IV |
|---|---|
| Baseline; n= 14 | 7.6423 ± 36.0 |
| Week 12; n= 13 | 7.2336 ± 31.5 |
| Week 28; n= 11 | 6.2740 ± 23.1 |
| Week 52; n= 7 | 5.8724 ± 18.6 |
| Week 76; n= 8 | 5.0211 ± 18.4 |
| Week 104; n= 10 | 4.8001 ± 24.5 |
| Week 128; n= 9 | 4.2407 ± 12.7 |
Serum cholesterol was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum cholesterol is defined as the mean of the Screening and Day 0 values and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| mmol/L | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; n= 13 | 0.9238 ± 16.8 |
| Week 28; n= 11 | 0.8896 ± 14.3 |
| Week 52; n= 7 | 0.8571 ± 16.7 |
| Week 76; n= 8 | 0.7111 ± 15.0 |
| Week 104; n= 10 | 0.6851 ± 17.3 |
| Week 128; n= 9 | 0.6140 ± 15.7 |
Serum IgG was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum IgG is defined as the pre-dose Day 0 value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| g/L | Belimumab 10 mg/kg IV |
|---|---|
| Baseline; n= 14 | 4.026 ± 1.6810 |
| Week 12; n= 13 | 3.871 ± 1.5266 |
| Week 28; n= 11 | 4.405 ± 1.7833 |
| Week 52; n= 8 | 5.823 ± 2.2572 |
| Week 76; n= 8 | 6.050 ± 2.1103 |
| Week 104; n= 10 | 7.611 ± 2.8301 |
| Week 128; n= 9 | 8.609 ± 2.2597 |
Serum IgG was assessed as a clinical chemistry laboratory parameter from Baseline up to Week 128/6 month follow-up visit. Baseline for serum IgG is defined as the pre-dose Day 0 value and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Ratio | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; n= 13 | 0.055 ± 0.6625 |
| Week 28; n= 11 | 0.469 ± 1.4287 |
| Week 52; n= 8 | 1.525 ± 2.4411 |
| Week 76; n= 8 | 1.619 ± 1.6681 |
| Week 104; n= 10 | 3.613 ± 2.5488 |
| Week 128; n= 9 | 4.334 ± 2.0289 |
Reduction of proteinuria lessens the risk of thromboembolic and cardiovascular effects and reduces the edema in participants. Investigators physically reviewed participants for clinical manifestations of idiopathic membranous glomerulonephropathy (IMGN) (e.g. edema extending beyond calf) during study and analysis was performed at Week 12, 28, 52, 76 Week 104. Only those participants available at the specified time points were analyzed (represented by n=X in category titles).
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| Week 0; oedema; n= 14 | 13 |
| Week 0; oedema extending beyond calf; n= 14 | 5 |
| Week 12; oedema; n= 12 | 9 |
| Week 12; Oedema extending beyond calf; n= 12 | 1 |
| Week 28;Oedema; n= 11 | 7 |
| Week 28; Oedema extending beyond calf; n= 11 | 1 |
| Week 52; oedema; n= 9 | 4 |
| Week 52;Oedema extending beyond calf; n= 9 | 1 |
| Week 76;Oedema; n=8 | 4 |
| Week 76;Oedema extending beyond calf; n= 8 | 0 |
| 4 Week post final dose (PFD); Oedema; n=10 | 6 |
| 4 Week PFD; Oedema extending beyond calf; n= 10 | 1 |
| Week 104 withdrawn (WD); Oedema; n= 1 | 0 |
| Week 104 WD;Oedema extending beyond calf; n= 1 | 0 |
The first occurrence of Cmax was determined directly from the serum concentration-time data. The pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis and all calculations of non-compartmental parameters are being based on actual sampling times.
| nanograms per milliliter (ng/mL) | Belimumab 10 mg/kg IV |
|---|---|
| Day 0, 5 minutes; n= 13 | 267996.0 ± 70598.02 |
| Week 28, 5 minutes; n= 11 | 312462.2 ± 95171.16 |
Trough concentration (Cmin) samples collected on the specified days are being used to assess attainment whether there was sufficient belimumab despite it being lost in the urine from the proteinuria and to check if it improved as proteinuria resolved. Analysis was performed on pre-infusion samples at weeks 2,4,8,12,28,40,52,76 and the 4 week post last-dose.
| ng/mL | Belimumab 10 mg/kg IV |
|---|---|
| Pre-infusion; Week 2; n= 14 | 29940.8 ± 20918.28 |
| Pre-infusion; Week 4; n= 12 | 41220.9 ± 35720.14 |
| Pre-infusion; Week 8; n= 13 | 30350.9 ± 25505.70 |
| Pre-infusion; Week 12; n= 11 | 30913.7 ± 30681.42 |
| Pre-infusion; Week 28; n= 11 | 34904.7 ± 26388.60 |
| Pre-infusion; Week 40; n= 10 | 40800.6 ± 28847.86 |
| Pre-infusion; Week 52; n= 9 | 38375.9 ± 14136.23 |
| Pre-infusion; Week 76; n= 8 | 65655.8 ± 32873.33 |
| 4 Weeks post last-dose; n= 9 | 60497.3 ± 28074.37 |
The AUC(0-2) was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Blood samples for PK analysis were collected at the following time points: pre-dose (on dosing days): Days 0, 1, 4, 7, 14 and Week 4, 8, 12, 28, 40, 52, 76 and 4 week post last dose. Post-dose (5 minutes after dosing complete): Days 0 and 28. The results will be posted at later date following post hoc analysis.
No measurements were reported for this outcome.
PK parameters from the urine concentration data: urine Ae(0-24) were assessed. 24 h urine collections for PK analysis were collected after the Day 0 and Weeks 12, 28, 52, 76 doses and at the 4 week post last dose visit. A population approach was undertaken to characterize the population PK parameters and associated variability of belimumab in nephrotic participants. The population approach could have provided derived clearance of belimumab for each participant after the first dose. The population PK analysis was conducted using nonlinear mixed-effect modeling (NONMEM) or appropriate nonlinear mixed-effect analysis software. Several samples were taken pre-dose at Day 0 and some at week 12 incorrectly which affects interpretation.
| ng/hour | Belimumab 10 mg/kg IV |
|---|---|
| Day 0; n= 14 | 105826.23 ± 178943.857 |
| Week 12; n= 12 | 95188.14 ± 130217.976 |
| Week 28; n= 11 | 92997.94 ± 110142.599 |
| Week 52; n= 9 | 219367.96 ± 391752.377 |
| Week 76; n= 8 | 145645.34 ± 267292.225 |
| 4 Week post last dose; n= 6 | 7909.34 ± 16771.559 |
Health-related quality of life was assessed through participant self-completion of the short form health survey (SF-36 version \[v2\]), a general health related quality of life metrics. Norm-based Scores (NBS) for physical functioning, role emotional, role physical were assessed. The remaining SF-36 component scores require re-scaling and therefore will be added at a later date. SF-36 was administered prior to any procedures at Weeks 12, 28, 52, 76 and 104/4 week post last dose. Item score were recorded and higher score represented better health status. Baseline is defined as Day 0 pre dose value and change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. Only those participants available at the specified time points were analyzed (represented by n=X in category titles).
| Scores on a scale | Belimumab 10 mg/kg IV |
|---|---|
| Physical functioning, Week 12; n= 12 | -4.034 ± 5.1907 |
| Physical functioning, Week 28; n= 11 | -0.765 ± 3.6780 |
| Physical functioning, Week 52; n= 9 | 0.468 ± 7.3489 |
| Physical functioning, Week 76; n= 7 | 0.601 ± 7.9409 |
| Physical functioning 4 Week post final dose;n=11 | 0.765 ± 11.7275 |
| Role emotional, Week 12; n= 12 | -0.000 ± 10.4831 |
| Role emotional, Week 28; n= 11 | 1.413 ± 15.1824 |
| Role emotional, Week 52; n= 9 | 3.023 ± 11.4621 |
| Role emotional, Week 76; n= 7 | 3.332 ± 7.2475 |
| Role emotional, 4 Week post final dose; n= 11 | 6.007 ± 10.0413 |
| Role physical, Week 12; n= 12 | 0.816 ± 11.0681 |
| Role physical, Week 28; n= 11 | 3.340 ± 8.4324 |
| Role physical, Week 52; n= 9 | 3.537 ± 9.1726 |
| Role physical, Week 76; n= 7 | 7.697 ± 12.2803 |
| Role physical 4 Week post final dose; n= 11 | 5.789 ± 11.4489 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The analysis was performed on Safety Population which comprised of all participants who were randomized into the study. SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, Requires hospitalization or prolongation of existing hospitalization, Results in disability/incapacity, is a congenital anomaly/birth defect, may require medical or surgical intervention, is associated with liver injury and impaired liver function.
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| AE | 14 |
| SAE | 3 |
Blood samples were collected from participants for evaluation of clinical chemistry and hematology parameters. The clinical chemistry parameters included albumin, alkaline phosphatase (alk.phosph.), alanine amino transferase (ALT), aspartate amino transferase (AST), total and direct bilirubin, calcium, cholesterol, chloride, carbon dioxide, creatinine, gamma glutamyl transferase (GGT), glucose, potassium, lactate dehydrogenase (LD), magnesium, sodium, phosphorus, total protein, blood urea nitrogen (BUN) and uric acid. The hematology parameters included basophils, eosinophil, hemoglobin, hematocrit, lymphocytes, monocytes, total neutrophils, platelets, red blood cells (RBC) count and white blood cells (WBC) count. Participants were counted in the category that their value changes to (low or high) for the specific time points. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| Albumin; Week 12; to high; n= 13 | 0 |
| Albumin; Week 12; to low; n= 13 | 0 |
| Albumin; Week 28; to high; n= 11 | 0 |
| Albumin; Week 28; to low; n= 11 | 0 |
| Albumin; Week 52; to high; n= 7 | 0 |
| Albumin; Week 52; to low; n= 7 | 0 |
| Albumin; Week 76; to high; n= 8 | 0 |
| Albumin; Week 76; to low; n= 8 | 0 |
| Albumin; Week 104; to high; n= 10 | 0 |
| Albumin; Week 104; to low; n= 10 | 0 |
| Albumin; 16 Week follow up; to high; n= 8 | 0 |
| Albumin; 16 Week follow up; to low; n= 8 | 0 |
| Alk.phosph.; Week 12; to high; n= 13 | 0 |
| Alk.phosph.; Week 12; to low; n= 13 | 0 |
| Alk.phosph.; Week 28; to high; n= 11 | 0 |
| Alk.phosph.; Week 28; to low; n= 11 | 0 |
| Alk.phosph.; Week 52; to high; n= 7 | 0 |
| Alk.phosph.; Week 52; to low; n= 7 | 0 |
| Alk.phosph.; Week 76; to high; n= 8 | 0 |
| Alk.phosph.; Week 76; to low; n= 8 | 0 |
| Alk.phosph.; Week 104; to high; n= 10 | 0 |
| Alk.phosph.; Week 104; to low; n= 10 | 0 |
| Alk.phosph.; 16 Week follow up; to high; n= 8 | 0 |
| Alk.phosph.; 16 Week follow up; to low; n= 8 | 0 |
| ALT; Week 12; to high; n= 13 | 0 |
| ALT; Week 12; to low; n= 13 | 0 |
| ALT; Week 28; to high; n= 11 | 0 |
| ALT; Week 28; to low; n= 11 | 0 |
| ALT; Week 52; to high; n= 7 | 0 |
| ALT; Week 52; to low; n= 7 | 0 |
| ALT; Week 76; to high; n= 8 | 0 |
| ALT; Week 76; to low; n= 8 | 0 |
| ALT; Week 104; to high; n= 10 | 0 |
| ALT; Week 104; to low; n= 10 | 0 |
| ALT; 16 Week follow up; to high; n= 8 | 0 |
| ALT; 16 Week follow up; to low; n= 8 | 0 |
| AST; Week 12; to high; n= 13 | 0 |
| AST; Week 12; to low; n= 13 | 0 |
| AST; Week 28; to high; n= 11 | 1 |
| AST; Week 28; to low; n= 11 | 0 |
| AST; Week 52; to high; n= 7 | 0 |
| AST; Week 52; to low; n= 7 | 0 |
| AST; Week 76; to high; n= 8 | 0 |
| AST; Week 76; to low; n= 8 | 0 |
| AST; Week 104; to high; n= 10 | 0 |
| AST; Week 104; to low; n= 10 | 0 |
| AST; 16 Week follow up; to high; n= 8 | 0 |
| AST; 16 Week follow up; to low; n= 8 | 0 |
| Direct bilirubin; Week 12; to high; n= 13 | 0 |
| Direct bilirubin; Week 12; to low; n= 13 | 0 |
| Direct bilirubin; Week 28; to high; n= 11 | 0 |
| Direct bilirubin; Week 28; to low; n= 11 | 0 |
| Direct bilirubin; Week 52; to high; n= 7 | 0 |
| Direct bilirubin; Week 52; to low; n= 7 | 0 |
| Direct bilirubin; Week 76; to high; n= 8 | 0 |
| Direct bilirubin; Week 76; to low; n= 8 | 0 |
| Direct bilirubin; Week 104; to high; n= 10 | 0 |
| Direct bilirubin; Week 104; to low; n= 10 | 0 |
| Direct bilirubin; 16 Week follow up; to high; n=8 | 0 |
| Direct bilirubin; 16 Week follow up; to low; n= 8 | 0 |
| Total bilirubin; Week 12; to high; n= 12 | 0 |
| Total bilirubin; Week 12; to low; n= 12 | 0 |
| Total bilirubin; Week 28; to high; n= 11 | 0 |
| Total bilirubin; Week 28; to low; n= 11 | 0 |
| Total bilirubin; Week 52; to high; n= 7 | 0 |
| Total bilirubin; Week 52; to low; n= 7 | 0 |
| Total bilirubin; Week 76; to high; n= 8 | 0 |
| Total bilirubin; Week 76; to low; n= 8 | 0 |
| Total bilirubin; Week 104; to high; n= 10 | 0 |
| Total bilirubin; Week 104; to low; n= 10 | 0 |
| Total bilirubin; 16 Week follow up; to high; n= 8 | 0 |
| Total bilirubin; 16 Week follow up; to low; n= 8 | 0 |
| Calcium; Week 12; to high; n= 12 | 0 |
| Calcium; Week 12; to low; n= 12 | 0 |
| Calcium; Week 28; to high; n= 11 | 0 |
| Calcium; Week 28; to low; n= 11 | 0 |
| Calcium; Week 52; to high; n= 7 | 0 |
| Calcium; Week 52; to low; n= 7 | 0 |
| Calcium; Week 76; to high; n= 8 | 0 |
| Calcium; Week 76; to low; n= 8 | 0 |
| Calcium; Week 104; to high; n= 10 | 1 |
| Calcium; Week 104; to low; n= 10 | 1 |
| Calcium; 16 Week follow up; to high; n= 8 | 0 |
| Calcium; 16 Week follow up; to low; n= 8 | 0 |
| Cholesterol; Week 12; to high; n= 13 | 0 |
| Cholesterol; Week 12; to low; n= 13 | 0 |
| Cholesterol; Week 28; to high; n= 11 | 0 |
| Cholesterol; Week 28; to low; n= 11 | 0 |
| Cholesterol; Week 52; to high; n= 7 | 0 |
| Cholesterol; Week 52; to low; n= 7 | 0 |
| Cholesterol; Week 76; to high; n= 8 | 0 |
| Cholesterol; Week 76; to low; n= 8 | 0 |
| Cholesterol; Week 104; to high; n= 10 | 0 |
| Cholesterol; Week 104; to low; n= 10 | 0 |
| Cholesterol; 16 Week follow up; to high; n= 8 | 0 |
| Cholesterol; 16 Week follow up; to low; n= 8 | 0 |
| Chloride; Week 12; to high; n= 13 | 1 |
| Chloride; Week 12; to low; n= 13 | 0 |
| Chloride; Week 28; to high; n= 11 | 2 |
| Chloride; Week 28; to low; n= 11 | 0 |
| Chloride; Week 52; to high; n= 7 | 0 |
| Chloride; Week 52; to low; n= 7 | 0 |
| Chloride; Week 76; to high; n= 8 | 0 |
| Chloride; Week 76; to low; n= 8 | 0 |
| Chloride; Week 104; to high; n= 10 | 0 |
| Chloride; Week 104; to low; n= 10 | 0 |
| Chloride; 16 Week follow up; to high; n= 8 | 0 |
| Chloride; 16 Week follow up; to low; n= 8 | 0 |
| Carbon dioxide; Week 12; to high; n= 13 | 0 |
| Carbon dioxide; Week 12; to low; n= 13 | 1 |
| Carbon dioxide; Week 28; to high; n= 11 | 0 |
| Carbon dioxide; Week 28; to low; n= 11 | 3 |
| Carbon dioxide; Week 52; to high; n= 7 | 0 |
| Carbon dioxide; Week 52; to low; n= 7 | 0 |
| Carbon dioxide; Week 76; to high; n= 8 | 0 |
| Carbon dioxide; Week 76; to low; n= 8 | 0 |
| Carbon dioxide; Week 104; to high; n= 10 | 0 |
| Carbon dioxide; Week 104; to low; n= 10 | 1 |
| Carbon dioxide; 16 Week follow up; to high; n= 8 | 0 |
| Carbon dioxide; 16 Week follow up; to low; n= 8 | 0 |
| Creatinine; Week 12; to high; n= 13 | 2 |
| Creatinine; Week 12; to low; n= 13 | 0 |
| Creatinine; Week 28; to high; n= 11 | 0 |
| Creatinine; Week 28; to low; n= 11 | 0 |
| Creatinine; Week 52; to high; n= 7 | 0 |
| Creatinine; Week 52; to low; n= 7 | 0 |
| Creatinine; Week 76; to high; n= 8 | 2 |
| Creatinine; Week 76; to low; n= 8 | 1 |
| Creatinine; Week 104; to high; n= 10 | 0 |
| Creatinine; Week 104; to low; n= 10 | 0 |
| Creatinine; 16 Week follow up; to high; n= 8 | 0 |
| Creatinine; 16 Week follow up; to low; n= 8 | 0 |
| GGT; Week 12; to high; n= 13 | 0 |
| GGT; Week 12; to low; n= 13 | 0 |
| GGT; Week 28; to high; n= 11 | 0 |
| GGT; Week 28; to low; n= 11 | 0 |
| GGT; Week 52; to high; n= 7 | 0 |
| GGT; Week 52; to low; n= 7 | 0 |
| GGT; Week 76; to high; n= 8 | 0 |
| GGT; Week 76; to low; n= 8 | 0 |
| GGT; Week 104; to high; n= 10 | 0 |
| GGT; Week 104; to low; n= 10 | 0 |
| GGT; 16 Week follow up; to high; n=8 | 0 |
| GGT; 16 Week follow up; to low; n= 8 | 0 |
| Glucose; Week 12; to high; n= 13 | 3 |
| Glucose; Week 12; to low; n= 13 | 0 |
| Glucose; Week 28; to high; n= 11 | 4 |
| Glucose; Week 28; to low; n= 11 | 0 |
| Glucose; Week 52; to high; n= 7 | 2 |
| Glucose; Week 52; to low; n= 7 | 0 |
| Glucose; Week 76; to high; n= 8 | 3 |
| Glucose; Week 76; to low; n= 8 | 0 |
| Glucose; Week 104; to high; n= 10 | 1 |
| Glucose; Week 104; to low; n= 10 | 0 |
| Glucose; 16 Week follow up; to high; n= 8 | 1 |
| Glucose; 16 Week follow up; to low; n= 8 | 1 |
| Potassium; Week 12; to high; n= 13 | 0 |
| Potassium; Week 12; to low; n= 13 | 0 |
| Potassium; Week 28; to high; n= 11 | 1 |
| Potassium; Week 28; to low; n= 11 | 1 |
| Potassium; Week 52; to high; n= 7 | 0 |
| Potassium; Week 52; to low; n= 7 | 0 |
| Potassium; Week 76; to high; n= 8 | 0 |
| Potassium; Week 76; to low; n= 8 | 0 |
| Potassium; Week 104; to high; n= 10 | 0 |
| Potassium; Week 104; to low; n= 10 | 0 |
| Potassium; 16 Week follow up; to high; n= 8 | 0 |
| Potassium; 16 Week follow up; to low; n= 8 | 0 |
| LD; Week 12; to high; n= 13 | 3 |
| LD; Week 12; to low; n= 13 | 0 |
| LD; Week 28; to high; n= 11 | 2 |
| LD; Week 28; to low; n= 11 | 0 |
| LD; Week 52; to high; n= 7 | 1 |
| LD; Week 52; to low; n= 7 | 0 |
| LD; Week 76; to high; n= 8 | 1 |
| LD; Week 76; to low; n= 8 | 0 |
| LD;Week 104; to high; n= 10 | 0 |
| LD;Week 104; to low; n= 10 | 0 |
| LD; 16 week follow-up; to high; n= 8 | 0 |
| LD; 16 week follow up; to low; n= 8 | 0 |
| Magnesium; Week 12; to high; n= 13 | 1 |
| Magnesium; Week 12; to low; n= 13 | 0 |
| Magnesium; Week 28; to high; n= 11 | 0 |
| Magnesium; Week 28; to low; n= 11 | 0 |
| Magnesium; Week 52; to high; n= 7 | 0 |
| Magnesium; Week 52; to low; n= 7 | 0 |
| Magnesium; Week 76; to high; n= 8 | 0 |
| Magnesium; Week 76; to low; n= 8 | 0 |
| Magnesium; Week 104; to high; n= 10 | 0 |
| Magnesium; Week 104; to low; n= 10 | 0 |
| Magnesium; 16 week follow up; to high; n= 8 | 0 |
| Magnesium; 16 week follow up; to low; n= 8 | 0 |
| Sodium; Week 12; to high; n= 12 | 0 |
| Sodium; Week 12; to low; n= 12 | 0 |
| Sodium; Week 28; to high; n= 11 | 0 |
| Sodium; Week 28; to low; n= 11 | 1 |
| Sodium; Week 52; to high; n= 7 | 0 |
| Sodium; Week 52; to low; n= 7 | 1 |
| Sodium; Week 76; to high; n= 8 | 0 |
| Sodium; Week 76; to low; n= 8 | 1 |
| Sodium; Week 104; to high; n= 10 | 0 |
| Sodium; Week 104; to low; n= 10 | 0 |
| Sodium; 16 week follow p; to high; n= 8 | 0 |
| Sodium; 16 week follow up; to low; n= 8 | 1 |
| Phosphorus; Week 12; to high; n= 13 | 1 |
| Phosphorus; Week 12; to low; n= 13 | 0 |
| Phosphorus; Week 28; to high; n= 11 | 2 |
| Phosphorus; Week 28; to low; n= 11 | 0 |
| Phosphorus; Week 52; to high; n= 7 | 0 |
| Phosphorus; Week 52; to low; n= 7 | 0 |
| Phosphorus; Week 76; to high; n= 8 | 0 |
| Phosphorus; Week 76; to low; n= 8 | 0 |
| Phosphorus;Week 104; to high; n= 10 | 1 |
| Phosphorus;Week 104; to low; n= 10 | 1 |
| Phosphorus; 16 week follow up; to high; n= 8 | 0 |
| Phosphorus; 16 week follow up; to low; n= 8 | 0 |
| Total protein; Week 12; to high; n= 12 | 0 |
| Total protein; Week 12; to low; n= 12 | 0 |
| Total protein; Week 28; to high; n= 11 | 0 |
| Total protein; Week 28; to low; n= 11 | 0 |
| Total protein; Week 52; to high; n= 7 | 0 |
| Total protein; Week 52; to low; n= 7 | 1 |
| Total protein; Week 76; to high; n= 8 | 0 |
| Total protein; Week 76; to low; n= 8 | 0 |
| Total protein; Week 104; to high; n= 10 | 0 |
| Total protein; Week 104; to low; n= 10 | 0 |
| Total protein; 16 Week follow up; to high; n= 8 | 0 |
| Total protein; 16 Week follow up; to low; n= 8 | 0 |
| BUN; Week 12; to high; n= 13 | 2 |
| BUN; Week 12; to low; n= 13 | 0 |
| BUN; Week 28; to high; n= 11 | 0 |
| BUN; Week 28; to low; n= 11 | 0 |
| BUN; Week 52; to high; n= 7 | 2 |
| BUN; Week 52; to low; n= 7 | 0 |
| BUN; Week 76; to high; n= 8 | 2 |
| BUN; Week 76; to low; n= 8 | 0 |
| BUN; Week 104; to high; n= 10 | 0 |
| BUN; Week 104; to low; n= 10 | 0 |
| BUN; 16 week follow up; to high; n= 8 | 0 |
| BUN; 16 week follow up; to low; n= 8 | 0 |
| Uric acid; Week 12; to high; n= 13 | 2 |
| Uric acid; Week 12; to low; n= 13 | 2 |
| Uric acid; Week 28; to high; n= 11 | 1 |
| Uric acid; Week 28; to low; n= 11 | 0 |
| Uric acid; Week 52; to high; n= 7 | 1 |
| Uric acid; Week 52; to low; n= 7 | 0 |
| Uric acid; Week 76; to high; n= 8 | 2 |
| Uric acid; Week 76; to low; n= 8 | 0 |
| Uric acid; Week 104; to high; n= 10 | 2 |
| Uric acid; Week 104; to low; n= 10 | 0 |
| Uric acid; 16 week follow up; to high; n= 8 | 2 |
| Uric acid; 16 week follow up; to low; n= 8 | 0 |
| Basophils; Week 12; to high; n= 12 | 0 |
| Basophils; Week 12; to low; n= 12 | 0 |
| Basophils; Week 28; to high; n= 11 | 0 |
| Basophils; Week 28; to low; n= 11 | 0 |
| Basophils; Week 52; to high; n= 9 | 0 |
| Basophils; Week 52; to low; n= 9 | 0 |
| Basophils; Week 76; to high; n= 8 | 0 |
| Basophils; Week 76; to low; n= 8 | 0 |
| Basophils; Week 104; to high; n= 9 | 0 |
| Basophils; Week 104; to low; n= 9 | 0 |
| Basophils; 16 week follow up; to high; n= 9 | 0 |
| Basophils; 16 week follow up; to low; n= 9 | 0 |
| Eosinophils; Week 12; to high; n= 12 | 1 |
| Eosinophils; Week 12; to low; n= 12 | 0 |
| Eosinophils; Week 28; to high; n= 11 | 1 |
| Eosinophils; Week 28; to low; n= 11 | 0 |
| Eosinophils; Week 52; to high; n= 9 | 0 |
| Eosinophils; Week 52; to low; n= 9 | 0 |
| Eosinophils; Week 76; to high; n= 8 | 1 |
| Eosinophils; Week 76; to low; n= 8 | 0 |
| Eosinophils; Week 104; to high; n= 9 | 0 |
| Eosinophils; Week 104; to low; n= 9 | 0 |
| Eosinophils; 16 week follow up; to high; n= 9 | 0 |
| Eosinophils; 16 week follow up; to low; n= 9 | 0 |
| Hemoglobin; Week 12; to high; n= 12 | 0 |
| Hemoglobin; Week 12; to low; n= 12 | 0 |
| Hemoglobin; Week 28; to high; n= 11 | 0 |
| Hemoglobin; Week 28; to low; n= 11 | 0 |
| Hemoglobin; Week 52; to high; n= 9 | 0 |
| Hemoglobin; Week 52; to low; n= 9 | 2 |
| Hemoglobin; Week 76; to high; n= 8 | 0 |
| Hemoglobin; Week 76; to low; n= 8 | 1 |
| Hemoglobin; Week 104; to high; n= 9 | 0 |
| Hemoglobin; Week 104; to low; n= 9 | 1 |
| Hemoglobin; 16 week follow up; to high; n= 9 | 0 |
| Hemoglobin; 16 week follow up; to low; n= 9 | 1 |
| Hematocrit; Week 12; to high; n= 12 | 0 |
| Hematocrit; Week 12; to low; n= 12 | 0 |
| Hematocrit; Week 28; to high; n= 11 | 1 |
| Hematocrit; Week 28; to low; n= 11 | 0 |
| Hematocrit; Week 52; to high; n= 9 | 0 |
| Hematocrit; Week 52; to low; n= 9 | 1 |
| Hematocrit; Week 76; to high; n= 8 | 0 |
| Hematocrit; Week 76; to low; n= 8 | 0 |
| Hematocrit; Week 104; to high; n= 9 | 0 |
| Hematocrit; Week 104; to low; n= 9 | 1 |
| Hematocrit; 16 week follow up; to high; n= 9 | 0 |
| Hematocrit; 16 week follow up; to low; n= 9 | 1 |
| Lymphocytes; Week 12; to high; n= 12 | 0 |
| Lymphocytes; Week 12; to low; n= 12 | 0 |
| Lymphocytes; Week 28; to high; n= 11 | 0 |
| Lymphocytes; Week 28; to low; n= 11 | 0 |
| Lymphocytes; Week 52; to high; n= 9 | 0 |
| Lymphocytes; Week 52; to low; n= 9 | 0 |
| Lymphocytes; Week 76; to high; n= 8 | 0 |
| Lymphocytes; Week 76; to low; n= 8 | 0 |
| Lymphocytes; Week 104; to high; n= 9 | 0 |
| Lymphocytes; Week 104; to low; n= 9 | 0 |
| Lymphocytes; 16 week follow up; to high; n= 9 | 0 |
| Lymphocytes; 16 week follow up; to low; n= 9 | 0 |
| Monocytes; Week 12; to high; n= 12 | 0 |
| Monocytes; Week 12; to low; n= 12 | 0 |
| Monocytes; Week 28; to high; n= 11 | 0 |
| Monocytes; Week 28; to low; n= 11 | 0 |
| Monocytes; Week 52; to high; n= 9 | 0 |
| Monocytes; Week 52; to low; n= 9 | 0 |
| Monocytes; Week 76; to high; n= 8 | 0 |
| Monocytes; Week 76; to low; n= 8 | 0 |
| Monocytes; Week 104; to high; n= 9 | 0 |
| Monocytes; Week 104; to low; n= 9 | 0 |
| Monocytes; 16 week follow up; to high; n= 9 | 0 |
| Monocytes; 16 week follow up; to low; n= 9 | 0 |
| Neutrophils; Week 12; to high; n= 12 | 1 |
| Neutrophils; Week 12; to low; n= 12 | 0 |
| Neutrophils; Week 28; to high; n= 11 | 0 |
| Neutrophils; Week 28; to low; n= 11 | 0 |
| Neutrophils; Week 52; to high; n= 9 | 0 |
| Neutrophils; Week 52; to low; n= 9 | 0 |
| Neutrophils; Week 76; to high; n= 8 | 0 |
| Neutrophils; Week 76; to low; n= 8 | 0 |
| Neutrophils; Week 104; to high; n= 9 | 2 |
| Neutrophils; Week 104; to low; n= 9 | 0 |
| Neutrophils; 16 week follow up; to high; n=9 | 1 |
| Neutrophils; 16 week follow up; to low; n= 9 | 0 |
| Platelet count; Week 12; to high; n= 12 | 3 |
| Platelet count; Week 12; to low; n= 12 | 0 |
| Platelet count; Week 28; to high; n= 11 | 2 |
| Platelet count; Week 28; to low; n= 11 | 0 |
| Platelet count; Week 52; to high; n= 9 | 0 |
| Platelet count; Week 52; to low; n= 9 | 0 |
| Platelet count; Week 76; to high; n= 8 | 0 |
| Platelet count; Week 76; to low; n= 8 | 0 |
| Platelet count; Week 104; to high; n= 9 | 1 |
| Platelet count; Week 104; to low; n= 9 | 0 |
| Platelet count; 16 week follow up; to high; n= 9 | 0 |
| Platelet count; 16 week follow up; to low; n= 9 | 0 |
| RBC; Week 12; to high; n= 12 | 0 |
| RBC; Week 12; to low; n= 12 | 3 |
| RBC; Week 28; to high; n= 11 | 0 |
| RBC; Week 28; to low; n= 11 | 1 |
| RBC; Week 52; to high; n= 9 | 0 |
| RBC; Week 52; to low; n= 9 | 1 |
| RBC; Week 76; to high; n= 8 | 0 |
| RBC; Week 76; to low; n= 8 | 0 |
| RBC; Week 104; to high; n= 9 | 0 |
| RBC; Week 104; to low; n= 9 | 0 |
| RBC; 16 week follow up; to high; n= 9 | 0 |
| RBC; 16 week follow up; to low; n= 9 | 1 |
| WBC; Week 12; to high; n= 12 | 1 |
| WBC; Week 12; to low; n= 12 | 0 |
| WBC; Week 28; to high; n= 11 | 0 |
| WBC; Week 28; to low; n= 11 | 0 |
| WBC; Week 52; to high; n= 9 | 0 |
| WBC; Week 52; to low; n= 9 | 0 |
| WBC; Week 76; to high; n= 8 | 0 |
| WBC; Week 76; to low; n= 8 | 0 |
| WBC; Week 104; to high; n= 9 | 2 |
| WBC; Week 104; to low; n= 9 | 0 |
| WBC; 16 week follow up; to high; n= 9 | 1 |
| WBC; 16 week follow up; to low; n= 9 | 0 |
Urine samples were collected for urinalysis by dipstick method from Baseline up to Week 116/16 months follow up and number of participants with findings were presented for Baseline, Week 12, 28, 52, 76, 104/4 weeks post last-dose and Week 116/16 week follow up (WF). The urinalysis parameters included occult blood, glucose, ketones, protein. The findings were presented as trace or 1/10 g/100 milliliter (dL), trace, negative, 4+, 3+, 3+ or 1 g/dL, 2+ or 1/2 g/dL, 2+, 1+ or 1/4 g/dL and 1+. Only participants present at the specific time points were presented (represented by n=X in the category titles).
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; occult blood; Trace or 1/10 g/DL; n= 12 | 0 |
| Week 12;Occult Blood; Trace; n= 12 | 1 |
| Week 12; Occult Blood; negative; n= 12 | 2 |
| Week 12; Occult Blood; 4+; n= 12 | 0 |
| Week 12; Occult Blood; 3+ OR 1 G/DL; n= 12 | 0 |
| Week 12; Occult Blood; 3+; n= 12 | 2 |
| Week 12; Occult Blood; 2+ OR 1/2 G/DL; n= 12 | 0 |
| Week 12; Occult Blood; 2+ ; n= 12 | 6 |
| Week 12; Occult Blood;1+ OR 1/4 G/DL; n= 12 | 0 |
| Week 12; Occult Blood; 1+; n= 12 | 1 |
| Week 12; glucose; Trace or 1/10 g/DL; n= 12 | 3 |
| Week 12;glucose; Trace; n= 12 | 0 |
| Week 12; glucose; negative; n= 12 | 8 |
| Week 12; glucose; 4+; n= 12 | 0 |
| Week 12; glucose; 3+ OR 1 G/DL; n= 12 | 0 |
| Week 12; glucose; 3+; n= 12 | 0 |
| Week 12; glucose; 2+ OR 1/2 G/DL; n= 12 | 0 |
| Week 12; glucose; 2+ ; n= 12 | 0 |
| Week 12; glucose;1+ OR 1/4 G/DL; n= 12 | 1 |
| Week 12; glucose; 1+; n= 12 | 0 |
| Week 12; ketones; Trace or 1/10 g/DL; n= 12 | 0 |
| Week 12; ketones; Trace; n= 12 | 0 |
| Week 12; ketones; negative; n= 12 | 12 |
| Week 12; ketones; 4+; n= 12 | 0 |
| Week 12; ketones; 3+ OR 1 G/DL; n= 12 | 0 |
| Week 12; ketones; 3+; n= 12 | 0 |
| Week 12; ketones; 2+ OR 1/2 G/DL; n= 12 | 0 |
| Week 12; ketones; 2+ ; n= 12 | 0 |
| Week 12; ketones;1+ OR 1/4 G/DL; n= 12 | 0 |
| Week 12; ketones; 1+; n= 12 | 0 |
| Week 12; protein; Trace or 1/10 g/DL; n= 12 | 0 |
| Week 12; Protein; Trace; n= 12 | 0 |
| Week 12; Protein; negative; n= 12 | 0 |
| Week 12; Protein; 4+; n= 12 | 0 |
| Week 12; Protein; 3+ OR 1 G/DL; n= 12 | 0 |
| Week 12; Protein; 3+; n= 12 | 8 |
| Week 12; Protein; 2+ OR 1/2 G/DL; n= 12 | 0 |
| Week 12; Protein; 2+ ; n= 12 | 3 |
| Week 12; Protein;1+ OR 1/4 G/DL; n= 12 | 0 |
| Week 12; Protein; 1+; n= 12 | 1 |
| Week 28; occult blood; Trace or 1/10 g/DL; n= 11 | 0 |
| Week 28;Occult Blood; Trace; n= 11 | 2 |
| Week 28; Occult Blood; negative; n= 11 | 1 |
| Week 28; Occult Blood; 4+; n= 11 | 0 |
| Week 28; Occult Blood; 3+ OR 1 G/DL; n= 11 | 0 |
| Week 28; Occult Blood; 3+; n= 11 | 0 |
| Week 28; Occult Blood; 2+ OR 1/2 G/DL; n= 11 | 0 |
| Week 28; Occult Blood; 2+ ; n= 11 | 4 |
| Week 28; Occult Blood;1+ OR 1/4 G/DL; n= 11 | 0 |
| Week 28; Occult Blood; 1+; n= 11 | 4 |
| Week 28; glucose; Trace or 1/10 g/DL; n= 11 | 1 |
| Week 28;glucose; Trace; n= 11 | 0 |
| Week 28; glucose; negative; n= 11 | 9 |
| Week 28; glucose; 4+; n= 11 | 0 |
| Week 28; glucose; 3+ OR 1 G/DL; n= 11 | 0 |
| Week 28; glucose; 3+; n= 11 | 0 |
| Week 28; glucose; 2+ OR 1/2 G/DL; n= 11 | 0 |
| Week 28; glucose; 2+ ; n= 11 | 0 |
| Week 28; glucose;1+ OR 1/4 G/DL; n= 11 | 1 |
| Week 28; glucose; 1+; n= 11 | 0 |
| Week 28; ketones; Trace or 1/10 g/DL; n= 11 | 0 |
| Week 28; ketones; Trace; n= 11 | 0 |
| Week 28; ketones; negative; n= 11 | 11 |
| Week 28; ketones; 4+; n= 11 | 0 |
| Week 28; ketones; 3+ OR 1 G/DL; n= 11 | 0 |
| Week 28; ketones; 3+; n= 11 | 0 |
| Week 28; ketones; 2+ OR 1/2 G/DL; n= 11 | 0 |
| Week 28; ketones; 2+ ; n= 11 | 0 |
| Week 28; ketones;1+ OR 1/4 G/DL; n= 11 | 0 |
| Week 28; ketones; 1+; n= 11 | 0 |
| Week 28; protein; Trace or 1/10 g/DL; n= 11 | 0 |
| Week 28; Protein; Trace; n= 11 | 0 |
| Week 28; Protein; negative; n= 11 | 0 |
| Week 28; protein; 4+; n= 11 | 0 |
| Week 28; Protein; 3+ OR 1 G/DL; n= 11 | 0 |
| Week 28; Protein; 3+; n= 11 | 10 |
| Week 28; Protein; 2+ OR 1/2 G/DL; n= 11 | 0 |
| Week 28; Protein; 2+ ; n= 11 | 1 |
| Week 28; Protein;1+ OR 1/4 G/DL; n= 11 | 0 |
| Week 28; Protein; 1+; n= 11 | 0 |
| Week 52; occult blood; Trace or 1/10 g/DL; n= 9 | 0 |
| Week 52;Occult Blood; Trace; n= 9 | 2 |
| Week 52; Occult Blood; negative; n= 9 | 3 |
| Week 52; Occult Blood; 4+; n= 9 | 0 |
| Week 52; Occult Blood; 3+ OR 1 G/DL; n= 9 | 0 |
| Week 52; Occult Blood; 3+; n= 9 | 0 |
| Week 52; Occult Blood; 2+ OR 1/2 G/DL; n= 9 | 0 |
| Week 52; Occult Blood; 2+ ; n= 9 | 4 |
| Week 52; Occult Blood;1+ OR 1/4 G/DL; n= 9 | 0 |
| Week 52; Occult Blood; 1+; n= 9 | 0 |
| Week 52; glucose; Trace or 1/10 g/DL; n= 9 | 2 |
| Week 52;glucose; Trace; n= 9 | 0 |
| Week 52; glucose; negative; n= 9 | 7 |
| Week 52; glucose; 4+; n= 9 | 0 |
| Week 52; glucose; 3+ OR 1 G/DL; n= 9 | 0 |
| Week 52; glucose; 3+; n= 9 | 0 |
| Week 52; glucose; 2+ OR 1/2 G/DL; n= 9 | 0 |
| Week 52; glucose; 2+ ; n= 9 | 0 |
| Week 52; glucose;1+ OR 1/4 G/DL; n= 9 | 0 |
| Week 52; glucose; 1+; n= 9 | 0 |
| Week 52; ketones; Trace or 1/10 g/DL; n= 9 | 0 |
| Week 52; ketones; Trace; n= 9 | 0 |
| Week 52; ketones; negative; n= 9 | 9 |
| Week 52; ketones; 4+; n= 9 | 0 |
| Week 52; ketones; 3+ OR 1 G/DL; n= 9 | 0 |
| Week 52; ketones; 3+; n= 9 | 0 |
| Week 52; ketones; 2+ OR 1/2 G/DL; n= 9 | 0 |
| Week 52; ketones; 2+ ; n= 9 | 0 |
| Week 52; ketones;1+ OR 1/4 G/DL; n= 9 | 0 |
| Week 52; ketones; 1+; n= 9 | 0 |
| Week 52; protein; Trace or 1/10 g/DL; n= 9 | 0 |
| Week 52; Protein; Trace; n= 9 | 0 |
| Week 52; Protein; negative; n= 9 | 0 |
| Week 52; protein; 4+; n= 9 | 0 |
| Week 52; Protein; 3+ OR 1 G/DL; n= 9 | 0 |
| Week 52; Protein; 3+; n= 9 | 4 |
| Week 52; Protein; 2+ OR 1/2 G/DL; n= 9 | 0 |
| Week 52; Protein; 2+ ; n= 9 | 3 |
| Week 52; Protein;1+ OR 1/4 G/DL; n= 9 | 0 |
| Week 52; Protein; 1+; n= 9 | 2 |
| Week 76; occult blood; Trace or 1/10 g/DL;n=7 | 0 |
| Week 76;Occult Blood; Trace; n= 7 | 3 |
| Week 76; Occult Blood; negative; n= 7 | 3 |
| Week 76; Occult Blood; 4+; n= 7 | 0 |
| Week 76; Occult Blood; 3+ OR 1 G/DL; n= 7 | 0 |
| Week 76; Occult Blood; 3+; n= 7 | 0 |
| Week 76; Occult Blood; 2+ OR 1/2 G/DL; n= 7 | 0 |
| Week 76; Occult Blood; 2+ ; n= 7 | 0 |
| Week 76; Occult Blood;1+ OR 1/4 G/DL; n= 7 | 0 |
| Week 76; Occult Blood; 1+; n= 7 | 1 |
| Week 76; glucose; Trace or 1/10 g/DL; n= 7 | 2 |
| Week 76;glucose; Trace; n= 7 | 0 |
| Week 76; glucose; negative; n= 7 | 5 |
| Week 76; glucose; 4+; n= 7 | 0 |
| Week 76; glucose; 3+ OR 1 G/DL; n= 7 | 0 |
| Week 76; glucose; 3+; n= 7 | 0 |
| Week 76; glucose; 2+ OR 1/2 G/DL; n= 7 | 0 |
| Week 76; glucose; 2+ ; n= 7 | 0 |
| Week 76; glucose;1+ OR 1/4 G/DL; n= 7 | 0 |
| Week 76; glucose; 1+; n= 7 | 0 |
| Week 76; ketones; Trace or 1/10 g/DL; n= 7 | 0 |
| Week 76; ketones; Trace; n= 7 | 0 |
| Week 76; ketones; negative; n= 7 | 7 |
| Week 76; ketones; 4+; n= 7 | 0 |
| Week 76; ketones; 3+ OR 1 G/DL; n= 7 | 0 |
| Week 76; ketones; 3+; n= 7 | 0 |
| Week 76; ketones; 2+ OR 1/2 G/DL; n= 7 | 0 |
| Week 76; ketones; 2+ ; n= 7 | 0 |
| Week 76; ketones;1+ OR 1/4 G/DL; n= 7 | 0 |
| Week 76; ketones; 1+; n= 7 | 0 |
| Week 76; protein; Trace or 1/10 g/DL; n= 7 | 0 |
| Week 76; Protein; Trace; n= 7 | 0 |
| Week 76; Protein; negative; n= 7 | 1 |
| Week 76; protein; 4+; n= 7 | 0 |
| Week 76; Protein; 3+ OR 1 G/DL; n= 7 | 0 |
| Week 76; Protein; 3+; n= 7 | 1 |
| Week 76; Protein; 2+ OR 1/2 G/DL; n= 7 | 0 |
| Week 76; Protein; 2+ ; n= 7 | 4 |
| Week 76; Protein;1+ OR 1/4 G/DL; n= 7 | 0 |
| Week 76; Protein; 1+; n= 7 | 1 |
| Week 104; occult blood; Trace or 1/10 g/DL;n=10 | 0 |
| Week 104;Occult Blood; Trace; n= 10 | 0 |
| Week 104; Occult Blood; negative; n= 10 | 8 |
| Week 104; Occult Blood; 4+; n= 10 | 0 |
| Week 104; Occult Blood; 3+ OR 1 G/DL; n= 10 | 0 |
| Week 104; Occult Blood; 3+; n= 10 | 0 |
| Week 104; Occult Blood; 2+ OR 1/2 G/DL; n= 10 | 0 |
| Week 104; Occult Blood; 2+ ; n=10 | 1 |
| Week 104; Occult Blood;1+ OR 1/4 G/DL; n= 10 | 0 |
| Week 104; Occult Blood; 1+; n= 10 | 1 |
| Week 104; glucose; Trace or 1/10 g/DL; n= 10 | 2 |
| Week 104 ;glucose; Trace; n= 10 | 0 |
| Week 104; glucose; negative; n= 10 | 7 |
| Week 104; glucose; 4+; n= 10 | 0 |
| Week 104; glucose; 3+ OR 1 G/DL; n= 10 | 0 |
| Week 104; glucose; 3+; n= 10 | 0 |
| Week 104; glucose; 2+ OR 1/2 G/DL; n= 10 | 0 |
| Week 104; glucose; 2+ ; n= 10 | 0 |
| Week 104; glucose;1+ OR 1/4 G/DL; n= 10 | 1 |
| Week 104; glucose; 1+; n= 10 | 0 |
| Week 104; ketones; Trace or 1/10 g/DL; n= 10 | 0 |
| Week 104; ketones; Trace; n= 10 | 0 |
| Week 104; ketones; negative; n= 10 | 10 |
| Week 104; ketones; 4+; n= 10 | 0 |
| Week 104; ketones; 3+ OR 1 G/DL; n= 10 | 0 |
| Week 104; ketones; 3+; n= 10 | 0 |
| Week 104; ketones; 2+ OR 1/2 G/DL; n= 10 | 0 |
| Week 104; ketones; 2+ ; n= 10 | 0 |
| Week 104; ketones;1+ OR 1/4 G/DL; n= 10 | 0 |
| Week 104; ketones; 1+; n= 10 | 0 |
| Week 104; protein; Trace or 1/10 g/DL; n= 10 | 0 |
| Week 104; Protein; Trace; n= 10 | 0 |
| Week 104; Protein; negative; n= 10 | 1 |
| Week 104; protein; 4+; n= 10 | 0 |
| Week 104; Protein; 3+ OR 1 G/DL; n= 10 | 0 |
| Week 104; Protein; 3+; n= 10 | 3 |
| Week 104; Protein; 2+ OR 1/2 G/DL; n= 10 | 0 |
| Week 104; Protein; 2+ ; n= 10 | 6 |
| Week 104; Protein;1+ OR 1/4 G/DL; n= 10 | 0 |
| Week 104; Protein; 1+; n= 10 | 0 |
| 16 WF; Occult blood; TRACE OR 1/10 G/DL; n= 9 | 0 |
| 16 WF; Occult blood; TRACE; n= 9 | 2 |
| 16 WF; Occult blood; NEGATIVE; n= 9 | 6 |
| 16 WF; Occult blood; 4+; n= 9 | 0 |
| 16 WF; Occult blood; 3+ OR 1 G/DL; n= 9 | 0 |
| 16 WF; Occult blood; 3+; n= 9 | 0 |
| 16 WF; Occult blood; 2+ OR 1/2 G/DL; n= 9 | 0 |
| 16 WF; Occult blood; 2+; n= 9 | 1 |
| 16 WF; Occult blood; 1+ OR 1/4 G/DL; n= 9 | 0 |
| 16 WF; Occult blood; 1+; n= 9 | 0 |
| 16 WF; Glucose; TRACE OR 1/10 G/DL; n= 9 | 1 |
| 16 WF; Glucose; TRACE; n= 9 | 0 |
| 16 WF; Glucose; negative; n= 9 | 7 |
| 16 WF; Glucose; 4+; n= 9 | 0 |
| 16 WF; Glucose; 3+ OR 1 G/DL; n= 9 | 0 |
| 16 WF; Glucose; 3+; n= 9 | 0 |
| 16 WF; Glucose; 2+ OR 1/2 G/DL; n= 9 | 1 |
| 16 WF; Glucose; 2+; n= 9 | 0 |
| 16 WF; Glucose; 1+ OR 1/4 G/DL; n=9 | 0 |
| 16 WF; Glucose; 1+; n=9 | 0 |
| 16 WF; Ketones; TRACE OR 1/10 G/DL; n= 9 | 0 |
| 16 WF; Ketones; TRACE; n= 9 | 0 |
| 16 WF; Ketones; negative; n= 9 | 9 |
| 16 WF; Ketones; 4+; n= 9 | 0 |
| 16 WF; Ketones; 3+ OR 1 G/DL; n= 9 | 0 |
| 16 WF; Ketones; 3+; n= 9 | 0 |
| 16 WF; Ketones; 2+ OR 1/2 G/DL; n= 9 | 0 |
| 16 WF; Ketones; 2+; n= 9 | 0 |
| 16 WF; Ketones; 1+ OR 1/4 G/DL; n= 9 | 0 |
| 16 WF; Ketones; 1+; n= 9 | 0 |
| 16 WF; Protein; TRACE OR 1/10 G/DL; n= 9 | 0 |
| 16 WF; Protein; TRACE; n= 9 | 1 |
| 16 WF; Protein; negative; n= 9 | 0 |
| 16 WF; Protein; 4+; n= 9 | 0 |
| 16 WF; Protein; 3+ OR 1 G/DL; n= 9 | 0 |
| 16 WF; Protein; 3+; n= 9 | 3 |
| 16 WF; Protein; 2+ OR 1/2 G/DL; n= 9 | 0 |
| 16 WF; Protein; 2+; n= 9 | 4 |
| 16 WF; Protein; 1+ OR 1/4 G/DL; n= 9 | 0 |
| 16 WF; Protein; 1+; n= 9 | 1 |
SBP and DBP were measured from Baseline throughout the treatment period up to Week 116/ 16 week follow-up visit. The Baseline value was taken at Day 0 pre dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean and standard deviation (SD) were measured and presented for Week 12, 28, 52, 76, 104 withdrawn visit, 4 Week post last dose and 16 Week follow-up visit. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| millimeter of mercury (mmHg) | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; SBP; n= 12 | -4.2 ± 17.23 |
| Week 28; SBP; n= 11 | -5.8 ± 18.14 |
| Week 52; SBP; n= 9 | -1.9 ± 18.66 |
| Week 76; SBP; n= 8 | -1.3 ± 11.30 |
| 4 Week post last dose; SBP; n= 10 | -12.2 ± 11.78 |
| 16 Week follow up; SBP; n= 9 | -7.4 ± 15.72 |
| Week 104 withdrawn visit; SBP; n= 2 | -1.0 ± 5.66 |
| Week 12; DBP; n= 12 | 3.8 ± 12.94 |
| Week 28; DBP; n= 11 | 0.8 ± 10.75 |
| Week 52; DBP; n= 9 | 1.2 ± 11.87 |
| Week 76; DBP; n= 8 | 2.8 ± 9.68 |
| 4 Week post last dose; DBP; n= 10 | -3.3 ± 9.87 |
| 16 Week follow up; DBP; n= 9 | 2.4 ± 14.98 |
| Week 104 withdrawn visit; DBP; n= 2 | 5.5 ± 2.12 |
Pulse rate was measured from Baseline throughout the treatment period up to Week 116/ 16 week follow-up visit. The Baseline value was taken at Day 0 pre dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean and standard deviation (SD) were measured and presented for Week 12, 28, 52, 76, 104 withdrawn visit, 4 Week post last dose and 16 Week post last dose visits. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Beats per minute | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; n= 12 | -0.7 ± 11.40 |
| Week 28; n= 11 | 1.0 ± 7.90 |
| Week 52; n= 9 | -1.7 ± 13.11 |
| Week 76; n= 8 | -2.3 ± 15.77 |
| 4 Week post last dose; n= 10 | -2.8 ± 15.33 |
| 16 Week follow up; n= 9 | -0.9 ± 16.72 |
| Week 104 withdrawn visit; n= 2 | 5.0 ± 7.07 |
Temperature was measured from Baseline throughout the treatment period up to Week 116/ 16 week follow-up visit. The Baseline value was taken at Day 0 pre dose and change from Baseline was defined as post dose visit value minus Baseline value. Mean and standard deviation (SD) were measured and presented for Week 12, 28, 52, 76, 104 withdrawn visit, 4 Week post last dose and 16 week post last dose visits. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Celsius | Belimumab 10 mg/kg IV |
|---|---|
| Week 12; n= 12 | -0.09 ± 0.591 |
| Week 28; n= 11 | -0.00 ± 0.453 |
| Week 52; n= 9 | -0.11 ± 0.639 |
| Week 76; n= 8 | -0.17 ± 0.486 |
| 4 Week post last dose; n= 8 | -0.06 ± 0.604 |
| 16 Week follow up; n= 6 | 0.30 ± 0.424 |
| Week 104 withdrawn visit; n= 2 | 0.15 ± 0.353 |
Blood samples of participants were collected pre-dose on Weeks 0, 12, 28, 40, 52, 76, 4 week post last dose and 16 week post last dose visit for belimumab immunogenicity assay. No participants showed positive immunogenicity findings.
| Participants | Belimumab 10 mg/kg IV |
|---|---|
| Number of Participants With Positive Immunogenicity Findings | 0 |
Urine membrane attack complex was assayed quantitatively by ELISA method. Urine MAC samples were collected at Day 0 and Weeks 8, 28, 52, 76 and 4 week post last dose. Results were normalized using urine creatinine concentration to adjust for urine dilution. Endpoint was moved to 'Exploratory' in Protocol amendment 5 as risk of availability of functioning assay for urine membrane attack complex was noted. No assay was subsequently found and samples were not analyzed
No measurements were reported for this outcome.
Urine membrane attack complex will be assayed quantitatively by ELISA method. Urine MAC samples are being collected at Day 0 and Weeks 8, 28, 52, 76 and 4 week post last dose. Results will be normalized using urine creatinine concentration to adjust for urine dilution, before calculation of the ratio as value at time point divided by value at Baseline (Day 0). Endpoint was changed to 'exploratory' as risk of availability of functioning assay for urine membrane attack complex was noted. No assay was subsequently found and samples were not analyzed.
No measurements were reported for this outcome.
B cell Facs panels were used to measure changes over the course of therapy in B cell subsets such as transitional, naïve, memory and plasma B cell compartments by percent of the B cell compartments and absolute numbers. T cell Facs panel were used to measure changes in T cell subsets, such as T regs and CD4+ and CD8+ T cells, in terms of numbers and expression of activation markers to establish if B cell targeting with belimumab affects the T cell compartment perhaps through limiting B cell antigen presentation or cytokine release. Baseline is defined as Day 0 value and change from Baseline was calculated as ratio of post-Baseline value divided by the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).
| Ratio | Belimumab 10 mg/kg IV |
|---|---|
| CD19+; Week 8; n= 12 | 0.7221 ± 82.1 |
| CD19+; Week 16; n= 11 | 0.9209 ± 63.6 |
| CD19+; Week 28; n= 10 | 1.0049 ± 71.6 |
| CD19+; Week 104; n= 10 | 0.5193 ± 156.2 |
| CD19+; 6 month follow up; n= 7 | 0.3828 ± 185.7 |
| CD19+ CD24b+ CD38b+ CD27-; Week 8; n= 12 | 0.2352 ± 340.0 |
| CD19+ CD24b+ CD38b+ CD27-; Week 16; n= 11 | 0.6228 ± 316.7 |
| CD19+ CD24b+ CD38b+ CD27-; Week 28; n= 10 | 0.6119 ± 656.0 |
| CD19+ CD24b+ CD38b+ CD27-; Week 104; n= 10 | 0.3582 ± 405.1 |
| CD19+ CD24b+ CD38b+ CD27-; 6 month follow up; n= 7 | 1.6471 ± 534.0 |
| CD19+ CD27- IgD+; Week 8; n= 12 | 0.3490 ± 131.6 |
| CD19+ CD27- IgD+; Week 16; n= 11 | 0.4486 ± 94.7 |
| CD19+ CD27- IgD+; Week 28; n= 10 | 0.4561 ± 82.5 |
| CD19+ CD27- IgD+; Week 104; n= 10 | 0.1808 ± 298.6 |
| CD19+ CD27- IgD+; 6 month follow up; n= 7 | 0.3278 ± 189.2 |
| CD19+ CD27-; Week 8; n= 12 | 0.4074 ± 109.2 |
| CD19+ CD27-; Week 16; n= 11 | 0.5079 ± 88.1 |
| CD19+ CD27-; Week 28; n= 10 | 0.5165 ± 76.5 |
| CD19+ CD27-; Week 104; n= 10 | 0.2602 ± 236.9 |
| CD19+ CD27-; 6 month follow up; n= 7 | 0.3756 ± 186.0 |
| CD19lo CD38hi CD27hi; Week 8; n= 12 | 0.5982 ± 555.4 |
| CD19lo CD38hi CD27hi; Week 16; n= 11 | 0.4128 ± 1085.7 |
| CD19lo CD38hi CD27hi; Week 28; n= 10 | 0.4481 ± 651.6 |
| CD19lo CD38hi CD27hi; Week 104; n= 10 | 0.2615 ± 238.8 |
| CD19lo CD38hi CD27hi; 6 month follow up; n= 7 | 0.0647 ± 1269.7 |
| CD19+ CD24+ CD27+ ; Week 8; n= 12 | 2.0747 ± 65.3 |
| CD19+ CD24+ CD27+ ; Week 16; n= 11 | 2.4161 ± 61.2 |
| CD19+ CD24+ CD27+ ; Week 28; n= 10 | 3.1294 ± 64.2 |
| CD19+ CD24+ CD27+ ; Week 104; n= 10 | 0.6089 ± 104014.8 |
| CD19+ CD24+ CD27+ ; 6 month follow up; n= 7 | 0.7952 ± 328.6 |
| CD19+CD27+; Week 8; n= 12 | 1.9195 ± 69.9 |
| CD19+CD27+; Week 16; n= 11 | 2.3132 ± 62.7 |
| CD19+CD27+; Week 28; n= 10 | 3.1352 ± 65.6 |
| CD19+CD27+; Week 104; n= 10 | 1.3273 ± 127.7 |
| CD19+CD27+; 6 month follow up; n= 7 | 0.3338 ± 158.2 |
| CD19+CD27+IgD; Week 8; n= 12 | 1.9365 ± 69.6 |
| CD19+CD27+IgD; Week 16; n= 11 | 2.3147 ± 75.1 |
| CD19+CD27+IgD; Week 28; n= 10 | 3.2313 ± 51.1 |
| CD19+CD27+IgD; Week 104; n= 10 | 1.2814 ± 102.3 |
| CD19+CD27+IgD; 6 month follow up; n= 7 | 0.2413 ± 163.9 |
| CD19+CD27+IgD-; Week 8; n= 12 | 1.8846 ± 67.7 |
| CD19+CD27+IgD-; Week 16; n= 11 | 2.2113 ± 70.4 |
| CD19+CD27+IgD-; Week 28; n= 10 | 3.0478 ± 73.2 |
| CD19+CD27+IgD-; Week 104; n= 10 | 1.3051 ± 147.1 |
| CD19+CD27+IgD-; 6 month follow up; n= 7 | 0.3440 ± 163.8 |
| CD4+ CD25hi CD45RA- IL7Rhi; Week 8; n= 12 | 0.7010 ± 86.7 |
| CD4+ CD25hi CD45RA- IL7Rhi; Week 16; n= 10 | 0.5340 ± 221.3 |
| CD4+ CD25hi CD45RA- IL7Rhi; Week 28; n= 9 | 0.5718 ± 669.2 |
| CD4+ CD25hi CD45RA- IL7Rhi; Week 104; n= 10 | 4.1865 ± 509.4 |
| CD4+ CD25hi CD45RA- IL7Rh; 6 month follow up; n= 7 | 1.8067 ± 1456.7 |
| CD4+ CD45RA- IL-7Rhi; Week 8; n= 12 | 1.4174 ± 19513.4 |
| CD4+ CD45RA- IL-7Rhi; Week 16; n= 10 | 1.8613 ± 99527.6 |
| CD4+ CD45RA- IL-7Rhi; Week 28; n=9 | 2.8378 ± 49940.7 |
| CD4+ CD45RA- IL-7Rhi; Week 104; n= 10 | 0.1517 ± 33534.3 |
| CD4+ CD45RA- IL-7Rhi; 6 month follow-up; n= 7 | 0.3532 ± 966.4 |
| CD4+ CD25hi xIL-7Rlo; Week 8; n= 12 | 0.7285 ± 85.7 |
| CD4+ CD25hi xIL-7Rlo; Week 16; n= 11 | 0.6232 ± 317.6 |
| CD4+ CD25hi xIL-7Rlo; Week 28; n= 10 | 0.7010 ± 961.5 |
| CD4+ CD25hi xIL-7Rlo; Week 104; n= 10 | 3.1025 ± 932.7 |
| CD4+ CD25hi xIL-7Rlo; 6 month follow-up; n= 7 | 2.0827 ± 832.7 |
| CD4+ CD25hi IL-7Rlo; Week 8; 12 | 2.3001 ± 29702.5 |
| CD4+ CD25hi IL-7Rlo; Week 16; n= 10 | 2.9023 ± 136702.6 |
| CD4+ CD25hi IL-7Rlo; Week 28; n= 9 | 3.3453 ± 35372.4 |
| CD4+ CD25hi IL-7Rlo; Week 104; n= 10 | 0.3410 ± 72506.2 |
| CD4+ CD25hi IL-7Rlo; 6 month follow up; n= 7 | 0.9978 ± 32.7 |
| CD4+ CD45RA-; Week 8; n= 12 | 0.7532 ± 44.5 |
| CD4+ CD45RA-; Week 16; n= 11 | 0.7638 ± 55.4 |
| CD4+ CD45RA-; Week 28; n= 10 | 0.9032 ± 71.1 |
| CD4+ CD45RA-; 104; n= 10 | 0.9750 ± 95.8 |
| CD4+ CD45RA-; 6 month follow up; n= 7 | 1.0792 ± 90.0 |
Cytokine/chemokine associated with T helper skewing or autoimmune pathology will be analyzed using Luminex, ELISA. Serum analyte quantification were used to confirm altered protein levels of any gene expression increases or decreases identified by transcriptomic analysis. Endpoint was moved to 'Exploratory' in Protocol amendment 5 as benefits of assessing cytokines was deemed low. Samples were not analyzed.
No measurements were reported for this outcome.
Free BLyS protein were analyzed using an ELISA. Serum samples were collected before treatment and after belimumab washout at Week 0 and Week 116/16 week follow-up visit.
| pg/mL | Belimumab 10 mg/kg IV |
|---|---|
| Day 0; n= 14 | 969.9595 ± 16.8 |
| 16 week follow up; n= 8 | 12357.5558 ± 123.3 |
B lymphocyte stimulator (BLyS) normalized by creatinine as a ratio of BLyS: creatinine. Free BLyS protein is being analyzed using an ELISA. Urine samples are being collected before treatment and after belimumab washout at Week 0 and Week 116/16 week follow-up visit. Only raw BLyS values available and unable to be assessed due to lack of comparison to a creatinine as a urine concentration marker.
No measurements were reported for this outcome.
Collected over On-therapy serious adverse events (SAEs) and non-serious adverse events (AEs) are presented from the start of study treatment up to end of study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belimumab 10 mg/kg IV | — | 3/14 (21.4%) | 14/14 (100%) |
| Event | Belimumab 10 mg/kg IV |
|---|---|
| CellulitisInfections and infestations | 1/14 |
| Weight decreasedInvestigations | 1/14 |
| EmbolismVascular disorders | 1/14 |
| Event | Belimumab 10 mg/kg IV |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 6/14 |
| Viral upper respiratory tract infectionInfections and infestations | 5/14 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 4/14 |
| Lower respiratory tract infectionInfections and infestations | 2/14 |
| RhinitisInfections and infestations | 2/14 |
| DiarrhoeaGastrointestinal disorders | 2/14 |
| DyspepsiaGastrointestinal disorders | 2/14 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/14 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/14 |
| HeadacheNervous system disorders | 2/14 |
| Age, Continuous(Years) | Belimumab 10 mg/kg IV |
|---|---|
| Mean | 46.1 ± 13.30 |
| Sex: Female, Male(Participants) | Belimumab 10 mg/kg IV |
|---|---|
| Female | 3 |
| Male | 11 |
| Race/Ethnicity, Customized(Participants) | Belimumab 10 mg/kg IV |
|---|---|
| Asian - Central/South Asian Heritage | 4 |
| White- White/Caucasian/European Heritage | 9 |
| Unknown | 1 |
The record gives a start of Jul 2012, a primary completion of Sep 2014 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Glomerulonephritis, Membranous →